|WPC 2013 Faculty|
Antoine Adamantidis (CANADA), graduated from University of Liege, Belgium (2005) and trained as a postdoctoral fellow at Stanford University, USA (2010). Since 2010, he is an assistant professor at the Department of Psychiatry, McGill University and the Douglas Mental Health University Institute, Montreal, Canada and was awarded the Canadian Research Chair in Optogenetics and neural circuits. Dr. Adamantidis’s objectives aim at investigating the wiring, dynamics and plasticity of the neural circuits regulating brain states during innate behaviour in normal and pathological states using in vitro and in vivo optogenetics combined to genetics and electophysiological methods. Together with his colleagues at Stanford University, he has pioneered the use of in vivo optogenetics to probe neural circuits controlling the wakefulness and sleep states. Optogenetics has opened new perspectives and unprecedented experimental strategies to assess the sufficiency or necessity of neuronal networks in selective behaviours, including arousal and reward. Eventually, his research will help to better understand the mechanisms underlying brain arousal and motivated behaviour and identify new therapeutic strategies through significant improvement of sleep conditions and pathologies associated with sleep disturbances including depression, schizophrenia and cognitive-related disorders.
Christine Albee (CANADA) joined the Government Relations and Public Affairs team at Canadian Diabetes Association in the spring of 2012. She has more than 15 years experience working at both Federal and Provincial levels of government, as well as experience in non-governmental organizations, and not-for-profit groups. She is a professional with expertise in all areas of government relations, including policy development, issues and crisis management, strategic planning and communication, and stakeholder relations and advocacy. Past roles have included senior positions within the federal departments of Science and Technology, the Federal Economic Development Agency of Southern Ontario, Citizenship and Immigration Canada, the Canada Revenue Agency, Western Economic Diversification and Natural Resources Canada. She has also served in the Office of the Premier of Ontario. Christine is a graduate of the University of Toronto with an academic focus on public relations, political science, communication and has a passion for social media and web design.
Roy Alcalay (USA), is an Assistant Professor of Neurology at the Taub Institute and the program director of the Movement Disorders Fellowship at the Columbia University Medical Center. He obtained his medical degree from Tel Aviv University, Israel, his neurology training from the Harvard University residency program at Massachusetts General Hospital and Brigham and Women’s Hospital and his movement disorders training at Columbia University. He is a graduate of the Patient Oriented Research and earned Master’s in biostatistics from Columbia University. His research focuses on biomarkers and genetics in Parkinson’s disease and cognitive functioning. He is a Brookdale Leadership in Aging fellow, and his research is supported by the NIH, the Parkinson’s Disease Foundation, the Smart Foundation and the Michael J Fox Foundation.
Roger A. Barker (UK), is the Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge and at Addenbrooke's Hospital. He trained at Oxford and London and has been in his current position for over ten years having completed an MRC Clinician Scientist Fellowship just prior to this. His main interests are in the neurodegenerative disorders of the nervous system in particular Parkinson's disease and Huntington's disease. He combines basic research looking at novel therapies (including cell transplants) to treat these conditions with clinically based work on defining the natural history and heterogeneity of both Huntington's disease and Parkinson's disease and is the co-ordinator of the FP7 TRANSEURO project looking at fetal cell grafting in patients with early PD.
Maria Barretto (INDIA) has a Ph.D. in Psychology from the University of Mumbai, India. She has over three decades of experience in the field of psychology, education and mental health and has designed, developed and conducted numerous programs for individuals with special needs. Dr Barretto is the CEO of the Parkinson’s Disease and Movement Disorder Society, (PDMDS) India. As CEO of the PDMDS, she has developed a multipronged approach to improving the quality of life with people with Parkinson’s Disease, encompassing raising awareness amongst the medical and allied health professionals and general public, developing training programs for all levels of stake holders, research and evidence - based interventions. In India, where Parkinson’s care is limited to a diagnosis and a medical prescription she has developed a ‘multidisciplinary community based’ model of care through which people with Parkinson’s are educated, treated, rehabilitated and brought back into the mainstream of society. The program is delivered through a group therapeutic approach which increases its reach and makes it cost effective given resource limitations. Her mission is to ‘Empower’ people living with Parkinson’s to improve the quality of their lives’.
Abdelhamid Benazzouz (FRANCE), is a Neurophysiologist Researcher employed by the INSERM institute working in a CNRS Unit in Bordeaux University. After completing a Master degree in Morocco, he went to Bordeaux to prepare his PhD diploma in the field of Neuroscience and Pharmacology that he obtained in 1993. During his PhD, he investigated a new therapeutical approach consisting of high frequency stimulation (HFS) of the subthalamic nucleus in a non-human primate model of Parkinson's disease. Then, at the end of 1993, he joined, as a Research Fellow, the Inserm unit of Professor Alim-Louis Benabid in Grenoble to participate in transfering this approach to patients. In parallel with his hospital activity as a Neurophysiologist, he was the head of a research group in the Inserm unit investigating the functional mechanisms of this approach in animal models. In 1998 he was appointed to Inserm position as a permanent position researcher. In 2001, he came back to Bordeaux as a PI in the CNRS unit of Professor Bernard Bioulac. In 2005 he was promoted to Research Director position. Presently he is the leader of the group « Monoamines, Deep Brain Stimulation & Parkinson's disease ». He has published more than 90 papers in peer-reviewed journals. Abdelhamid Benazzouz obtained the National Academy of Medicine award in 2003 and the Academy of Science award in 2007.
Bonnie Bereskin (CANADA), was the Professional Practice Leader in Speech-Language Pathology at a Toronto teaching hospital and a Clinical Educator at the University of Toronto Graduate School of Speech-Language Pathology. In that capacity she collaborated to develop and implement a multi-disciplinary Parkinson self-management program. It provided intervention and education to clients with Parkinson’s and Parkinson Plus disorders. She is now in private practice with a focus on assisting individuals along the Parkinson continuum with their communication and swallowing problems. She brings to the discussion many years of experience as a clinician. The focus of her practice is in helping Parkinsonians and their families develop and sustain communication throughout the Parkinson journey. Her clients include individuals with more rapidly progressive Parkinson Plus disorders, such as MSA and PSP. Since on-going speech therapy, over many years, is not available to most, Bonnie partners with her clients to develop cost-effective approaches to maintaining communication and participation in social activities.
Daniela Berg (GERMANY): After completion of studies at the Medical School at the University of Würzburg in 1994 and finishing her doctoral thesis, Prof. Daniela Berg started practical training in neurology and psychiatry in Würzburg, Germany. In 2002 she received the board certification as neurologist and worked from 2002 to 2004 as Postdoc at the Department of Human Genetics at the University Tübingen, followed by two years as Senior Resident at the Department of Neurology. In 2004 she completed her habilitation. Since 2006, Prof. Berg is working as Senior physician at the University Hospital in Tübingen, Centre of Neurology, Department of Neurodegeneration. She is leading the working group "Clinical Neurodegeneration” and is head of the outpatients’ clinic for Parkinsonian syndromes and RLS, responsible coordinator of clinical studies and head of the Ultrasound Lab. Primary aim of the clinical work of her group is individualized and patient-centered therapy. Her main interests of research comprise the early and differential diagnosis of neurodegenerative disorders, particularly the detection and validation of risk and biomarkers for diagnosis and progression of Parkinson’s disease. Prof. Berg is chair of the Movement Disorders Task Force on the "Definition of Parkinson’s Disease” and is member of the Scientific Advisory Board of the German Parkinson’s Disease Association (dPV). In 1999 she received the Parkinson Price of the German Society for Neurology for her pionieering work on transcranial sonography in movement disorders, in 2001 the Dissertation Prize for Science of the UnterfränkischenGedenkjahrstiftung and in 2004 a Parkinson Research Grant of the Hilde-Ulrichs-Stiftung.
Erwan Bezard (FRANCE), INSERM Research Director, has authored or co-authored over 160 professional publications in the field of neurobiology, most of which are on Parkinson's disease and related disorders. Listed in the Top 1% of the most cited neuroscientists (H factor=35; Source: ISI), he is best known for his work on the compensatory mechanisms that mask the progression Parkinson's disease and on the pathophysiology of levodopa-induced dyskinesia. His current research interests include the study of the compensatory mechanisms, the levodopa-induced dyskinesia, the basic pathophysiology of basal ganglia circuitry, and the development of new strategies to alleviate symptoms and/or to slow disease progression. Bezard is the director of a new CNRS research unit located in Bordeaux, the Institute of Neurodegenerative Diseases, that features preclinical and clinical researchers working towards development of therapeutic solutions. He is also a Visiting Professor at the China Academy of Medical Sciences (Beijing, China) where he has set-up and manages a non-human primate facility dedicated to Movement Disorders. He serves on the board of international organizations such as the International Basal Ganglia Society and the Michael J. Fox Foundation. He is Associate Editor of Neurobiology of Disease and of Movement Disorders, two leading journals in the field. He serves on the editorial boards of several other neurobiology journals. Besides consulting for several drug companies in the field of movement disorders, he is a non-executive director of Plenitudes Sarl (France), Motac Neuroscience (UK) and Motac Cognition (USA).
Pierre Blanchet (CANADA) is a neurologist, associate professor at the Faculty of Dental Medicine, Universite de Montreal, and neurologist at Notre-Dame Hospital (CHU Montreal) and Louis-H. Lafontaine Hospital (Mental Health University Institute of Montreal ). He is interested in movement disorders and uses both basic and clinical approaches to advance knowledge in the field. He is pursuing clinical studies involving Parkinson's Disease patients and subjects with orofacial dyskinesias.
Bastiaan Bloem (NETHERLANDS) is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. He received his M.D. degree (with honour) at Leiden University Medical Centre in 1993. In 1994, Professor Bloem obtained his PhD degree in Leiden, based on a thesis entitled "Postural reflexes in Parkinson's disease”. He was trained as a neurologist between 1994 and 2000, also at Leiden University Medical Centre. He received additional training as a movement disorders specialist during fellowships at ‘The Parkinson's Institute', Sunnyvale, California (with Dr. J.W. Langston), and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell). In 2002, he founded and became Medical Director of the Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson's disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative healthcare concept that now consists of 64 professional networks for Parkinson patients covering all of the Netherlands ( www.parkinsonnet.nl ). In September 2008, he was appointed as Professor of Neurology, with movement disorders as special area of interest. He is currently President of the International Society for Gait and Postural Research, and is on the editorial board for several national and international journals. Since 2009, he is member of the European Section Executive Committee of the Movement Disorder Society. In 2009, he also joined the board of ZonMw (The Netherlands Organisation for Health Research and Development). He currently has two main research interests: cerebral compensatory mechanisms, especially in the field of gait & balance; and healthcare innovation, aiming to develop and scientifically evaluate patient-centred collaborative care. For this latter purpose, Professor Bloem co-founded MijnZorgnet (together with Prof. Jan Kremer), a service provider that delivers web-based communities for both patients and health professionals. Professor Bloem has published over 300 publications, including more than 230 peer-reviewed international papers.
Nicolaas Bohnen (USA), is Professor of Radiology and Neurology at the University of Michigan, Ann Arbor, MI. He attended medical school in the Netherlands and completed a PhD in neuropsychology. He completed residency training in neurology (Mayo Clinic, Rochester, MN) and nuclear medicine (University of Michigan, Ann Arbor, MI). He was a fellow in movement disorders at the University of Michigan Medical Center. He holds clinical appointments in the Departments of Radiology (Division of Nuclear Medicine), Neurology at the University of Michigan and the Ann Arbor VA where he directs the movement disorders clinic. Dr. Bohnen’s research interests include the use of PET and MRI in the study of neurodegenerative disorders and normal aging. He is the Director of the UM Functional Neuroimaging, Cognitive and Mobility Laboratory where his clinical research has a focus on neurobiological correlates of mobility and cognition in normal aging and Parkinson disease and biomarker development for the diagnosis and treatment monitoring in Parkinson disease. He also studies olfactory function tests as biomarkers to screen for neurodegenerative disorders, such as Parkinson or Alzheimer disease, and to determine risk of conversion to dementia. His research is funded by grants from the NIH, the Department of Veterans Affairs, and the Michael J. Fox Foundation.
Nathalie Bolduc (CANADA) is a genetic counsellor at the Department of Medical Genetics at the McGill University Health Centre (MUHC) in Montreal, Canada. She obtained her Master’s degree in Genetic Counselling from McGill University. Throughout her practice, she developed an expertise in several clinical settings including predictive testing for cancer genetics, prenatal diagnosis, reproductive technologies, pediatric genetics and adult genetics. In 2008, she became the point person for genetic services and for predictive testing for Huntington disease in the province of Quebec.
Elaine Book (USA), is the Clinic Social Worker and Center Leader for the NPF Center of Excellence, the Pacific Parkinson’s Research Centre, at the University of British Columbia in Vancouver, Canada. Elaine earned her BSW from the University of Manitoba and her MSW from the University of British Columbia with her thesis focusing on caregiver stress. Elaine has worked in the field of Social Work for over 25 years in a variety of community and hospital settings with an interest in the geriatric population. Social work roles have included individual and family work as well as work as a leader of support groups. Continuing education has been ongoing and has included training in cognitive behavioral therapy, advance care planning and social work instruction as well as older adult suicide and abuse. Elaine has also been a speaker at several PD support group meetings and neurology meetings. Elaine continues to co-ordinate the neuro social worker blog Elaine’s dedication to improving the lives of people with Parkinson’s is greatly influenced by the determination of the patients she works with on a daily basis. Elaine may be contacted at firstname.lastname@example.org
Scott Brady (USA) received his undergraduate training in Biology and Physics at MIT before earning his Ph.D. in Cell and Molecular Biology from the University of Southern California. His graduate studies and then his subsequent postdoctoral training with Dr. Raymond Lasek led to a longstanding interest in the molecular mechanisms of axonal transport and the role of molecular motors in neuronal function. He pioneered the use of isolated axoplasm from the squid giant axon||and continues to use this preparation during summer research at the Marine Biological Laboratory in Woods Hole, MA, where he was one of the discoverers of the kinesin family of molecular motors. In recent years, he has increasingly focused on the regulation of axonal transport and the role that compromises in axonal transport play in adult onset neurodegenerative diseases. He has been interested in how pathogenic forms of neuronal proteins alter signaling pathways in neurons that affect the transport and targeting of neuronal proteins. He and his associates have demonstrated that mutant SOD1 and damaged wild type SOD1 both activate the P38 MAP kinase pathway and inhibit kinesin based transport, implicating pathogenic SOD1 in many cases of both familial and sporadic ALS.
Gila Bronner (ISRAEL) is a certified sex therapist and the director of the Sex Therapy Service (in the Sexual Medicine Center, Sheba Medical Center, Israel). Since 1984 Gila has been training physicians and health professionals in coping with issues of sexual health promotion, sexual rehabilitation and sex education. In 1997- 2003 Gila worked as a sex therapist in the departments of neurology, psychiatry, oncology and cardiology (Tel-Aviv Medical Center), contributing to a multidisciplinary approach.
In the neurologic department she specialized in treating patients with Parkinson's disease (PD), epilepsy, multiple sclerosis and CVA. Focusing on sexual aspects of PD, enabled Gila to construct a multidisciplinary approach to coping with sexual changes in PD patients and their partners. In cooperation with the Israeli PD association, Gila is organizing special PD training for health professional (nurses, physiotherapists, speech therapists, psychologists and occupational therapist).
Gila's volunteer work involves counseling
and leading the Israeli Family Planning Association (1985-2000), the Israeli
association of sex therapists (2002-2010), as well as active contribution to
the EPDA (European Parkinson's disease association) and to various national and
international PD organizations.
She has published scientific articles, chapters in scientific books, sex education books for children, adolescents and elders and articles in the media. Her international activities include training of physicians and healthcare professionals in Portugal, Canada, Croatia, Czech Rep., Slovenia, Ireland, Australia, Korea, Greece, Scotland, Germany, Trinidad, USA and Cyprus. She was the chair-person of the scientific committee of the European congress of sexology 2002, and a member of the scientific committees of the World Congress of Sexology 2005, 2007, 2010 and 2013.Her language proficiency includes: English and Hebrew (very good), German (good), French, Spanish & Polish (fair).
David Brooks (UK), MD DSc FRCP(UK) FMed Sci (UK) is Hartnett Professor of Neurology and Deputy Head of the Division of Neuroscience in the Department of Medicine, Imperial College, London. He is also Professor of Neurology at Aarhus University, Denmark. He has served on the Research Advisory Panels of the UK Parkinson's Disease Society, the German Dementia and Parkinson Networks, and INSERM. He was a member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Disease Research (2002-2006), UK Medical Research Council Neuroscience and Mental Health Board (2004-2007), and was Chairman of the Scientific Issues Committee of the Movement Disorder Society (1998-2002). He is an Associate Editor of Brain and is on the Editorial Boards of the Journal of Parkinson's Disease, Parkinsonism and Related Disorders, and Basal Ganglia. He was on the Editorial Board of Movement Disorders 1994-1998. In 2001 he was elected a Fellow of the Academy of Medical Science, UK. His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer's and Parkinson's disease.
Patrik Brundin (USA) is the Director of the Center for Neurodegenerative Science (CNS) and the inaugural holder of the Jay Van Andel Endowed Chair in Parkinson Research.
Dr.Brundin is an internationally renowned expert in the field of Parkinson’s and neurodegenerative disease research with a career in this area that spans almost 30 years, including key involvement in some of the first neural transplantation trials to treat the disease in humans. He obtained his M.D. and Ph.D. at Lund University in Sweden where he is currently a Professor of Neuroscience leading a research group focused on the pathogenesis of Parkinson’s and Huntington’s and cell-based approaches for therapy and treatment. He is the editor-in-chief of the Journal of Parkinson’s Disease. He is one of the most cited researchers in his area of research and has coordinated several prestigious and multidisciplinary research networks across Europe specializing in Parkinson’s research.
David Burn (UK) is Professor of Movement Disorder Neurology at Newcastle University and Honorary Consultant Neurologist for Newcastle upon Tyne Hospitals Foundation Trust. He is Director of the University’s Institute for Ageing and Health, Director of Newcastle Biomedicine’s Clinical Ageing Research Unit and a Senior NIHR Investigator. He qualified from Oxford University and Newcastle upon Tyne Medical School in 1985. His MD was in the functional imaging of parkinsonism. He runs the Movement Disorders service in Newcastle upon Tyne which provides a large regional service. Research interests include dementia associated with Parkinson’s disease and progressive supranuclear palsy. He was a member of the Special Interest Committee Task Force of the International Movement Disorder Society for Diagnostic Criteria for Parkinsonian Disorders (2002-3) and the Parkinson’s disease Dementia Task Force (2004-6). He was appointed NIHR-DeNDRoN Associate Director/National Lead for Parkinson’s||disease in July 2010. He was Clinical Reviews Editor for the Movement Disorder Journal from January 2007 before taking on an Associate Editorial role in||January 2010. Professor Burn was elected to the International Executive Committee of the Movement Disorder Society in June 2009 and is currently Chair of the MDS Congress Scientific Programme Committee. He has published over 200 articles on movement disorders in peer reviewed journals.
Jean Burns (USA) is a former web developer and software trainer. She was diagnosed with Parkinson’s disease in 2003 and soon after became an active Parkinson’s advocate. She has received both the Alan Bonander Humanitarian Award and the Milly Kondracke Award for her service to the Parkinson’s community. Jean and her friend, Sheryl Jedlinski, founded PDPLan4life.com in 2007. Their goal is to share their stories of "living well with Parkinson’s disease.” Over the seven years of its existence, PDPlan4life.com has had over 80,000 visits from all over the world. Nearly 1,000 readers from around the world receive e-notifications when a new web page has been posted.
Fulvio Capitanio (SPAIN) is an economist and ITC manager. He was diagnosed with Parkinson's in 2007 and retired from his job in 2009. In January of 2008, with a group of PD friends he met over the Internet, he started an online organization called 'Unidos contra el Parkinson” (together against Parkinson's disease) at http://portal.unidoscontraelparkinson.com. Since October 2009 Fulvio coordinated every two years the UCP International Meeting in Spain dedicated to promote the importance of complementary therapies in PD treatment. In March 2010 Unidos contra el Parkinson edited a comic 'Through the eyes of a child” to help parents to explain PD to their children. In April 2010 started the project 'Run 4 PD”, a worldwide yearly event involving cities from different countries to run and walk miles to raise awareness on PD. Fulvio is now dedicated to help and assess young onset people with PD.
M. Angela Cenci (SWEDEN) is a Professor of Experimental Medical Research at Lund University (Lund, Sweden), where she heads the Basal Ganglia Pathophysiology Unit. Her research activities address the pathophysiology of Parkinson’s disease and other movement disorders originating from the basal ganglia (L-DOPA-induced dyskinesia, graft-induced dyskinesia, and Huntington´s disease). Several ongoing projects aim at developing new symptomatic or neurorestorative/neuroprotective treatments for the above conditions. The Basal Ganglia Pathophysiology Unit is a partner in several EU-funded project consortia, and in centres of excellence for PD research that are supported by the Swedish National Research Council (Multipark, www.med.lu.se/multipark; BAGADILICO, www.med.lu.se/bagadilico; and the Neuronano Research Centre, www.med.lu.se/nrc). Cenci has advisory appointments at several national and international research organizations, including the Swedish Movement Disorder Society (from 2003); NECTAR (Network of European CNS Transplantation and Restoration) (from 2005); The International Movement Disorders Society (from 2009); The Swedish Parkinson Research Network (from 2010); The M.J. Fox Foundation for Parkinson’s Research (from 2010); The International Brain Research Organisation (IBRO, from 2012).
Sreeganga Chandra (USA) is an Assistant Professor at Yale University. Her lab investigates genetic forms of Parkinson's disease as well as mechanisms of synapse maintenance.
Ray Chaudhuri (UK) is a Professor in Neurology/Movement Disorders and Consultant Neurologist and at Kings College and Institute of Psychiatry, London an Academic Health Sciences Centre and also principal investigator at the MRC centre for neurodegeneration research at Kings College, London. He is the medical director of the National Parkinson Foundation International Centre of Excellence at Kings College, London. He sits on the Nervous Systems Committee of UK Department of Health, National Institute of Health Research and also serves as co-chairman of the appointments/liaison committee of the Movement Disorders Society and is currently serving as the member of the scientific programme committee of the MDS. He serves on the task force of practice parameter group for PD and RLS and more recently Non Motor Symptoms of Parkinson's, American Academy Neurology. He is the European Editor of Basal Ganglia and is in the editorial board of Parkinsonism and Related Disorders and Journal of Parkinson's Disease. He is also the lead for London South CLRN neurosciences sub-speciality group. He is the current Chairman of the Pakinson's non motor study group of the MDS. Professor Ray Chaudhuri is the author of 215 papers including reviews, book chapters, co-editor of 4 books on Parkinson's disease and Restless Legs Syndrome and over 200 published peer reviewed abstracts. He is the chief editor of the first comprehensive textbook on non motor aspects of Parkinson's ,published by Oxford University Press and recipient of BMA book prize commendation prize. He has contributed extensively to educational radio and television interviews including BBC and CNN, newspaper articles and videos. He has also lectured extensively on PD and restless legs syndrome at international meetings in USA, Japan, continental Europe, South America, South Africa, India and Australia. His major research interests are continuous drug delivery treatment of PD and restless legs syndrome, Parkisnonism in minority ethnic groups and sleep problems in PD. In 2005 he was awarded the DSc degree by the University of London.
Marie-Francoise Chesselet (USA) received her M.D. and Ph.D. degrees from the University of Paris VI, in France. She completed her internship at the Hopital de l'Hotel Dieu in Paris and her PhD thesis in the laboratory of Jacques Glowinski at the College of France. After obtaining a position at the CNRS, she joined the laboratory of Ann Graybiel at MIT and the laboratory of Michael Bronstein at the NIH as a Visiting Scientist. She held faculty appointments at the Medical College of Pennsylvania and the University of Pennsylvania before joining UCLA as the Charles H. Markham Professor of Neurology in 1996. She is currently Chair of the Department of Neurobiology in the David Geffen School of Medicine at UCLA. She is also Director of the APDA Advanced Center for Parkinson's Disease Research, Morris K. Udall Center of Excellence for Parkinson's Disease Research and the Center for Gene Environment Studies in Parkinson's Disease at UCLA.
Sylvain Chouinard (CANADA) has obtained his MD at the University of Montreal. He did is fellowship in movement disorders under the supervision of Dr Stanley Fahn at Columbia Presbyterian Medical Center in New York City. He is the founder of the Andre-Barbeau Movement Disorders Unit that is now located at the Notre-Dame Hospital of the Centre Hospitalier Universitaire de Montréal (CHUM). Involved in research since 1997, his major interests are in the diagnosis and treatment of movement disorders such as Parkinson’s disease, dystonia, Huntington’s disease and tremor. He acts as Principal Investigator in numerous studies exploring the efficacy of treatments, and the genetic aspects of Parkinson’s and Huntington’s diseases, as well as dystonia. A major part of Dr Chouinard’s time is dedicated to the diagnosis and treatment of movement disorders with an emphasis on Parkinson, Huntington and dystonia.
Charleen T. Chu (USA) is Professor of Pathology at the University of Pittsburgh School of Medicine. She serves as the Director of Ophthalmic Pathology, and Co-Director of the Pathologist Investigator Residency-Research Training Program. Dr. Chu trained in the Medical Scientist Training Program at Duke University, receiving her PhD in Pathology-Biochemistry. She is board certified in Anatomic Pathology and Neuropathology, completing fellowship training in Ophthalmic Pathology and post-doctoral training in molecular biology and cell signaling at Duke University. Dr. Chu is a member of the American Society for Clinical Investigation Honor Society, receiving the ASIP Outstanding Investigator Award, the Carnegie Science Award for Emerging Female Scientist, and an AFAR Dorothy Dillon Eweson Advances in Aging Research Award Lectureship. Dr. Chu leads a multidisciplinary research team focused on cellular quality control in Parkinson’s disease. Using oxidative and genetic models in concert with post-mortem patient samples, Dr. Chu’s team discovered a key role for altered mitochondrial targeting of kinases, accompanied by decreased nuclear signaling. This led to seminal work in the post-translational regulation of neuronal autophagy and mitochondrial biogenesis, employing molecular, live cell imaging and mass spectrometry/proteomic approaches. Dr. Chu has authored numerous primary publications, including 3 Faculty of 1000-recommended articles in journals such as J Cell Biol, J Biol Chem, Cell Death Differ, Hum Mol Genet, J Neurosci, and Am J Pathol. She serves as chartered or ad hoc member of NIH study sections, Associate Editor of the journal Autophagy, Academic Editor for PLoS ONE and Autophagy Section Editor for Current Pathobiology Reports, co-editing the book Autophagy of the Nervous System (World Scientific Publishing Co, Singapore, 2012). Her laboratory is supported by funding from the National Institutes of Health (NIA, NINDS) and the American Federation for Aging Research/Ellison Medical Foundation.
Timothy J. Collier (USA) is a Professor in the Department of Translational Science & Molecular Medicine, Edwin A. Brophy Endowed Chair in Central Nervous System Disorders and Director of the Udall Center of Excellence in Parkinson’s Disease Research at Michigan State University. Dr. Collier trained at the University of Minnesota, Northwestern University and the University of Rochester. More than fifteen years ago he became a member of a four principal investigator collaborative team that has been studying issues of dopamine neuron biology as they apply to aging, Parkinson’s disease and experimental therapeutics. Dr. Collier is a past president of the American Society for Neural Therapy and Repair, past chairperson of the NIH CNNT study section, past Associate Editor of the European Journal of Neuroscience, and has published over 100 peer reviewed scientific reports.
Diane Cook (USA) is a management consultant who specializes in training and leadership development. She was diagnosed with Parkinson’s disease in 2008, completed the Parkinson’s Disease Foundation’s (PDF) Parkinson’s Advocates in Research (PAIR) training in 2009 and went on to establish two popular support groups for patients newly diagnosed with PD. She is an active advocate of research, having participated in nine clinical trials or research studies herself and has facilitated the enlistment of hundreds of others. She serves on the PDF People with Parkinson’s Advisory Council (PPAC). She co-presented an abstract at the 2nd World Parkinson’s Congress on her program for newly diagnosed Parkinson’s patients. Diane is currently a Co-Investigator, along with her neurologist, of a research study assessing the impact on disease outcomes of a self-efficacy learning curriculum she designed for patients newly diagnosed with PD. She serves on the Board of Directors of the Colorado Neurological Institute and was the recipient of their Hope Award for her education activities and serving as an inspiration to others. Diane is Colorado State Director for the Parkinson’s Action Network (PAN) and Senior Patient Advocate for the ProjectSpark Foundation, a foundation established by her children which offers grants for innovative projects directed at improving the lives of those with PD. She actively tweets about Parkinson’s topics @NewPWP. She is a graduate of Smith College.
Diane Côté (CANADA) is a Registered Nurse in the Parkinson’s Disease and Movement Disorders Clinic at The Ottawa Hospital. Prior to this position she taught Nursing and Pharmacology at the Health Sciences Department of La Cité Collégiale. She also participated in a broad range of Phase I to IV clinical research trials, in Rheumatology, Multiple Sclerosis, Oncology, and Infectious diseases. For the last 6 years, she has specialized in clinic nursing and coordinating studies with the Ottawa Hospital Research Institute, related to Parkinson’s Disease. She is co-founder of Parkinson’s Stepping Forward, a charitable organization which offers a form of music therapy for people living with Parkinson’s and their caregivers. She volunteers in many activities including fundraising and informative sessions about Parkinson. Her goal is to promote health and a better quality of life to the people with neurological disease.
Sharon Daborn (AUSTRALIA), WPC Ambassador Montreal 2013 was diagnosed with PD at age 31. She became aware of the WPC through the video competition for the 2010 Glasgow congress. As a result of the video and attending the WPC, Sharon was able to further strengthen links within the early onset community in Victoria, being invited to assist in the co-ordination of the first Australian National Young Onset Conference, which was held November 2010 in Melbourne. Committed to establishing a strong state, national and international young PWPs network, She recently worked on the launch of the Victorian Young Onset website and currently am working on establishing a secure online social support network for the under 40s with PD. Blessed with three beautiful daughters, Sharon is honoured to be working as an Ambassador for the WPC, promoting the organization that inspired me to tell her story and has changed her life.
Peter Davison (CANADA) is an international motivational speaker and adversity author based in Halifax, Nova Scotia. He speaks, trains and writes to celebrate everyday unsung heroes who help others succeed. Peter has celebrated the joy of speaking and the business of making a difference since 1985 with the maxim: Go Forth, Do Good, Stay Blessed - Repeat as Necessary. Peter was diagnosed with "young onset” Parkinson's Disease at age 45 in 2005. He is the author of the best-selling book 'Gift of the Hit' that chronicles his grateful journey with embracing the adversity of Parkinson's. His keynote 'The Four Dimensions of Living Well with Parkinson's' routinely receives standing ovations from audiences wearing their new clown noses. Peter has been quoted in Oprah Magazine, is proud to be a first time Dad, twice, at age 50 and has a weakness for chocolate.
Ted Dawson (USA) is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases in the Departments of Neurology and Neuroscience and the Graduate Program in Cellular & Molecular and the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. He is the Scientific Director of the Institute for Cell Engineering and he is the Director of the Johns Hopkins University School of Medicine's Morris K. Udall Parkinson's Disease Research Center of Excellence. Dr. Dawson is world-renowned for his novel contributions on the role of nitric oxide in neuronal injury. He has published over 400 full-length manuscripts and review articles. He is one of the top five cited Neuroscientists in the last decade. Dr. Dawson has won several awards including the Derek Denny-Brown Young Neurological Scholar Award, the Paul Beeson Physician Faculty Scholar Award, the Santiago Grisolia Medal and the ISI Highly Cited Researcher Award. He was elected to the Association of American Physicians and he is a Fellow of the American Association for the Advancement of Science. He is the Chairman of Scientific Advisory Board of the Bachman-Strauss Dystonia and Parkinson Foundation and serves on the Medical Advisory Board of the Society for Progressive Supranuclear Palsy and he is a member of the Faculty of 1000 Biology Neurobiology of Disease and Regeneration Section of the Neuroscience Faculty. Many advances in neurobiology of disease have stemmed from Dr. Dawson's identification of the mechanisms of neuronal cell death and the elucidation of the molecular mechanisms of neurodegeneration. He pioneered the role of nitric oxide in neuronal injury in stroke and excitotoxicity and elucidated the molecular mechanisms by which nitric oxide and poly (ADP-ribose) polymerase and apoptosis inducing factor kills neurons. His studies of nitric oxide led to major insights into the neurotransmitter functions of this gaseous messenger molecule. He discovered the neurotrophic properties of non-immunosuppressant immunophilin ligands. Dr. Dawson has been at the forefront of research into the biology and pathobiology of the proteins and mutant proteins linked to Parkinson's disease. These studies are providing major insights into understanding the pathogenesis of PD and are providing novel opportunities for therapies aimed at preventing the degenerative process of PD and other neurodegenerative disorders.
Steve DeWitte (USA) was first diagnosed with Parkinson disease in March of 2005 at the age of 48. In October 2006, he established and co-facilitates the Young On Set Support Group of Connecticut. Steve has co-created or hosted programs for the Michael J. Fox Foundation and the American Parkinson Disease Association, and is a 2008 graduate from the inaugural Clinical Resource Learning Institute (CRLI) presented by the Parkinson Disease Foundation (PDF). Steve currently serves as a Connecticut Congressional liaison for the Parkinson Action Network (PAN), and is also a member of the PDF People with Parkinson Action Committee (PPAC). As a full time Parkinson advocate, Steve provides presentations on various issues, most prominently on the subjects of "The Role of the Parkinson Patient”, which emphasizes participation in clinical trials and value of support groups. Steve has participated in over seven clinical trials.
He has used his previous professional experiences to benefit various charities in the areas of volunteer recruitment, marketing, event management, fundraising and strategic planning.
Steve, his wife Teri, and daughter Katie live in Washington, CT.
Nico Diederich (LUXEMBOURG) is a clinical neurologist. He studied at the Universities of Homburg/Saar and Bonn (Germany) and trained in neurology at the University of Cologne (Germany) and at Rush University, Chicago (USA). He wrote his doctoral thesis on the involvement of the sympathetic and parasympathetic nervous system in the genesis of hypertension and his "Habilitation” on clinical non motor symptoms in Parkinson’s disease (PD), with special emphasis on hallucinations and sleep fragmentation. Since 2011, Dr. Diederich is the "ausserplanmässiger Professor für Neurologie" at the University of Cologne (Germany) and he regularly teaches at this University. As a Visiting Assistant Professor, he annually returns to Rush University, Chicago for mini-sabbaticals. His clinical practice is at CHL in Luxembourg-City (Luxembourg). While treating there inpatients and outpatients with any neurological condition, his main clinical and scientific interests and focus are movement disorders and sleep disorders. In particular, Dr. Diederich is involved in longitudinal studies on various non motor symptoms in early stages of Parkinson’s disease (PD) and in network analysis of these symptoms. His team is mainly interested in visual, olfactory, autonomic and sleep dysfunction. He has recently joined the Luxembourg Centre for Systems Biomedicine (LCSB) as a Senior Clinical Researcher and is presently setting up a translational research collaboration between LCSB and CHL in order to examine different "omics”, especially concerning mitochondrial dysfunction in various tissues derived from PD patients, and to correlate the findings with the evolution of motor and non motor signs in PD patients
Roseanne Dobkin (USA) is an Associate Professor of Psychiatry at UMDNJ-Robert Wood Johnson Medical School, in Piscataway, NJ USA. She is also a licensed clinical psychologist. Dr. Dobkin received her Ph.D. in Clinical Psychology from the Medical College of Pennsylvania- Hahnemann University in Philadelphia, PA in August 2002 and completed a postdoctoral fellowship in Clinical Psychopharmacology, in the Department of Psychiatry at Robert Wood Johnson Medical School, in September 2003, prior to joining the faculty. The majority of her research and clinical work over the past 10 years has focused on the non-medication treatment of the psychiatric complications (i.e., depression, anxiety, insomnia, cognition) in Parkinson’s disease (PD). To date, her research program has addressed the efficacy of face-to-face Cognitive-Behavioral Treatment (CBT) for depression in Parkinson’s disease (dPD) in a randomized controlled trial, as well as the development and pilot-testing of a telephone-based CBT intervention for dPD. She has also begun to systematically examine barriers to mental health care utilization in PD. Dr. Dobkin's research is currently funded by the National Institutes of Health and the Patterson Trust Awards Program in Clinical Research.
Nicolas Dupré (CANADA) trained in Neurogenetics at McGill University (Montreal Neurologic Hospital) and Harvard University (MGH). He is presently Director of the Neurogenetics Clinic of the CHU de Québec and Associate Professor at the Faculty of Medicine, Laval University. He has been involved over the last decade in the discovery of genes responsible for rare forms of movement disorders as well as motor neuron diseases.
Gammon Earhart (USA), is a neuroscientist and physical therapist whose research focuses on the neural control of movement with an emphasis on motor control in Parkinson disease. She received her physical therapy training at Arcadia University, her PhD in Movement Science from Washington University in St. Louis, and completed a postdoctoral fellowship at Oregon Health & Science University. Dr. Earhart is currently Associate Professor of Physical Therapy, Anatomy & Neurobiology, and Neurology at Washington University School of Medicine, where she directs the Locomotor Control Laboratory and the Movement Science PhD Program. Her research on dance as therapy for Parkinson disease began in 2006 and has been funded by multiple sources included the Parkinson's Disease Foundation, the American Parkinson Disease Association and the National Institutes of Health.
David Eidelberg (USA) is the Director of the Center for Neurosciences and the NIH Morris K. Udall Center of Excellence for Parkinson’s Disease Research at the Feinstein Institute for Medical Research in Manhasset, New York. Dr. Eidelberg is internationally recognized for his pioneering work using functional imaging to identify abnormal functional brain networks in neurological disorders. Dr. Eidelberg's work has led to the development of novel image-based methods for the assessment of disease progression, treatment response, and to enhance the accuracy of clinical diagnosis.
Dr. Eidelberg received his MD from Harvard Medical School. After completing residency training in neurology at the Harvard-Longwood Area Training Program, he pursued postdoctoral training as a Moseley Traveling Fellow at the National Hospital, Queen Square in London UK and at Sloan-Kettering Institute in New York. Dr. Eidelberg moved to North Shore University Hospital in Manhasset, New York in 1988 to establish the functional imaging laboratory and the clinical movement disorders program. In 2001 he became the founding director of the Center for Neurosciences at The Feinstein Institute for Medical Research, where he is currently Susan and Leonard Feinstein Professor of Neurology and Neuroscience.
Dr. Eidelberg has received many grants and awards, including the Fred Springer Award (2005) and the American Academy of Neurology Movement Disorders Research Award (2010). He is the author of over 350 peer-reviewed scientific articles and reviews and serves on the editorial boards of The Journal of Neuroscience, Annals of Neurology, NeuroImage, and the Journal of Nuclear Medicine. Dr. Eidelberg currently serves on the scientific advisory board of The Michael J. Fox Foundation.
Robin Elliott (USA) has been Executive Director of the Parkinson's Disease Foundation, Inc. (PDF) since October 1996. In the last 17 years, Mr. Elliott’s vision has ushered in a new age for PDF, fortifying PDF’s programs of research, education and advocacy for the Parkinson’s community. Under his leadership, the professional staff has grown from just four full-time employees to more than 20 and the PDF budget has more than tripled, rising from $2.7 million in 1996 to over $10 million in fiscal year 2013.
He has been active in fostering collaborations amongst Parkinson’s organizations, including negotiating a merger with the Chicago-based United Parkinson’s Foundation in 1998. He also played an instrumental role in the creation and organization of the World Parkinson Congress in 2006 and in the conception of the PDtrials campaign, an initiative of the major Parkinson's patient voluntary groups to accelerate the development of new treatments for the disease.
Active in development, communications and nonprofit management in New York City for more than 30 years, Mr. Elliott has served as vice president for development and external affairs at Teachers College, Columbia University (1988-95) and (with the same title) at Hunter College, The City University of New York (1982-88); as deputy to the Chancellor for University Relations at the City University of New York (1979-82); and as director of information and education at the Planned Parenthood Federation of America (1971-79).
Mr. Elliott currently serves as Chairman of the board for the Community Health Charities of New York,Treasurer ofthe board for the American Society for Experimental NeuroTherapeutics (ASENT), Chair of the board for the American Brain Coalition (ABC) and board member of the Empire State Stem Cell Board (ESSCB). He was formerly Chair of New Yorkers for the Advancement of Medical Research, a pro-stem-cell research coalition of disease advocacy groups, scientists and universities, and citizens’ groups.
Elliott grew up in southern England and received his formal education at
Bradfield (a preparatory school; 1954-59); Magdalen College, Oxford University
(B.A. in Philosophy, Politics and Economics, 1962); and Columbia University
(M.A. in American Government and Politics, 1965).
Terry Ellis (USA), is an Assistant Professor at Boston University, College of Health & Rehabilitation Sciences in the Department of Physical Therapy & Athletic Training. Her research focuses on investigating the impact of exercise and rehabilitation on the progression of disability in individuals with Parkinson disease. She has a particular interest in identifying barriers to exercise and developing interventions to help persons with Parkinson disease overcome these barriers to engage in lifelong exercise. Dr. Ellis is the Director of the Center for Neurorehabilitation at Boston University and the Director of the American Parkinson Disease Association National Rehabilitation Resource Center housed at Boston University. Dr. Ellis has a Ph.D. in Behavioral Neurosciences from Boston University School of Medicine. She has published numerous articles and lectures internationally on topics related to rehabilitation in persons with Parkinson disease.
Stewart Factor (USA) is the Professor and Director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine. He received his medical degree at the New York College of Osteopathic Medicine of the New York Institute of Technology. Residency training was at Albany Medical Center in Albany, New York and Fellowship training in Parkinson’s disease and Movement Disorders at the University of Miami. He is currently a member of the American Academy of Neurology, American Neurological Association, Movement Disorder Society, Parkinson, Huntington, and Dystonia Study Groups. He is past Chair of the Movement Disorders Section of the American Academy of Neurology. He has held the following committee memberships: for the AAN Movement Disorder Section Executive Committee, for MDS education committee, Archives committee, PSG nominating committee and budget committee and HSG executive committee and nominating committee. He has edited three textbooks: "Parkinson’s Disease: Diagnosis and Clinical Management” first & second editions and "Drug-induced Movement Disorders” as well as authoring numerous articles. Current research projects include participation in the NeuroGenetics Research Consortium, a genetic examination of families with Parkinson’s disease, the Michael J Fox Foundation sponsored Parkinson Progression Marker Initiative (PPMI), studies of environment and PD along with several clinical trials.
Stanley Fahn (USA), founder and President of the World Parkinson Coalition, and co-chair of the first two World Parkinson Congresses, will stay on board as co-chair of the WPC 2013.
When asked about this role with the WPC, he said, "I am honored and pleased to co-chair the third World Parkinson Congress with Dr. Stoessl. I look forward to seeing the WPC 2013 expand beyond what the first two WPCs offered to make the experience for delegates as rich as possible with opportunities to learn about the latest science and to meet a wider array of members of the Parkinson's community than they would find at any other Parkinson's meeting today. Allowing people with PD, neuroscientists, rehab specialists, clinicians and others to interact with each other is such a special experience and one that many delegates will remember for years following the Congress. The enthusiasm and "buzz” generated by people with Parkinsons at the first two Congresses made those events extremely exciting. I expect the same at WPC2013, and I am delighted to be a part of this Congress and look forward to seeing many familiar and new faces in Montreal in October 2013.”
Dr. Fahn is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University Medical Center . He is the Past-President of the American Academy of Neurology (AAN). He founded the Movement Disorder Society and served as the Chairman of its Steering Committee and was elected its first president. He was the founding co editor of the journal Movement Disorders, and also served as Associate Editor of Neurology for 10 years.
Dr. Fahn has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. He currently serves on an NIH Oversight Committee to review and give advice on clinical trials on neuroprotection for PD. Dr. Fahn and his scientific colleagues at Columbia University were awarded a Morris K. Udall Parkinson's Disease Research Center of Excellence by the National Institutes of Health in 1999, and it is currently ongoing. Dr. Fahn organized and executed the development of the Unified Parkinson's Disease Rating Scale (UPDRS) and modified and popularized the use of the Schwab England ADL score for global severity of this disease. Both of these rating scores are used worldwide, the former to determine the severity of PD, and the latter as a measure of quality of life. He has participated in many clinical trials of a variety of pharmacotherapeutic agents for PD.
Along with Dr. Ira Shoulson; Dr. Fahn was a co founder of the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conduct controlled clinical trials on the prevention and treatment of Parkinson's disease. He has received numerous honors and delivered many titled lectures at a variety of universities around the world.
Matthew Farrer (CANADA), Canada Excellence Research Chair in Neurogenetics and Translational Neuroscience and Dr. Donald Rix BC Leadership Chair in Genetic Medicine, is pioneering the field of molecular neuroscience. A prolific scientist, Dr. Farrer is described as having made some of the greatest contributions to Parkinson’s disease research over the past decade. An expert in the field of molecular genetics, Dr. Farrer has made several influential discoveries in neurogenetics and is critically acclaimed for this work on the genetics of Parkinson’s disease. Dr. Farrer and his team, at the Centre for Applied Neurogenetics within the Department of Medical Genetics at the University of British Columbia, are using cutting-edge sequencing technology to define the Parkinson’s genome by identifying new genes and mutations, and what specific changes these cause to the brain’s biological network. He has worked with patient populations and families worldwide and his molecular insights have led to model systems that are helping to define the biological processes perturbed by the genetic mutations. The discoveries have laid the foundation for new and effective therapies.
His work has been funded by CIHR, the Cundill foundation, the Michael J. Fox Foundation and the Parkinson Disease Foundation. He is a member of the Michael J. Fox Foundation’s Executive Scientific Board and the Parkinson’s Society of Canada Scientific Advisory Board.
Howard Federoff (USA), as Executive Vice President for Health Sciences at Georgetown University and Executive Dean of the School of Medicine, Dr. Federoff is responsible for Georgetown University Medical Center (GUMC). He is a professor of Neurology and Neuroscience Prior to Georgetown, he held appointments as Senior Associate Dean for Basic Research; Professor of Neurology, Medicine Microbiology and Immunology; and Professor of Oncology and Genetics at the University of Rochester School of Medicine, and as Founding Director of the Center for Aging and Development Biology at the Aab Institute of Biomedical Sciences and Founding Division Chief of Molecular Medicine and Gene Therapy. After joining the Rochester faculty in 1995, he also served as Director of the University of Rochester’s Interdepartmental Neuroscience Program. Dr. Federoff’s research interests include gene therapy and neurodegenerative diseases such as Parkinson’s, and Alzheimer’s. His research has received support from the NSF, the NIH, and the DOD. He has published widely in peer-reviewed journals and served as a reviewer for many journals, and currently serves on the editorial boards of the Journal of Parkinson’s Disease, Open Genomics Journal and Journal Experimental Neurology. Dr. Federoff served as Chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He is a Fellow of the AAAS and National Academy of Inventors. Before joining the Rochester community, he was Associate Professor of Medicine and Neuroscience at Albert Einstein College of Medicine, from which he received MS, PhD, and MD degrees. He did his internship, residency, and clinical and research fellowships at Massachusetts General Hospital/Harvard Medical School, and practiced medicine at the Albert Einstein College of Medicine and University of Rochester. He resides in Washington with his wife, Wendy Solovay, Esq. His two daughters, Allison and Monica, are currently pursuing graduate studies in law and medicine, respectively.
Hubert Fernandez (USA) is Head of Program for Movement Disorders in the Center for Neurological Restoration at Cleveland Clinic in Cleveland, Ohio.
Dr Fernandez received both his BS degree in Biology and his MD degree in the Philippines. He completed his internship in internal medicine at University of Pennsylvania/Pennsylvania Hospital in Philadelphia, Pennsylvania; his residency in neurology at Boston University Medical Center in Boston, Massachusetts; and his fellowship in movement disorders at Brown University/Memorial Hospital in Pawtucket, Rhode Island.
Dr Fernandez is an internationally recognized expert in movement disorders who has been voted one of the Best Doctors in America by his peers. After completing his medical training in 1999, he joined the faculty of Brown University School of Medicine as Assistant Professor of the Department of Clinical Neurosciences and served as Associate Director of the Movement Disorders Unit at Memorial Hospital and Neurological Director of its Functional Neurosurgical Program. In 2003, Dr Fernandez relocated to the University of Florida, where he eventually became Director of the Clinical Research Unit for Neurological and Psychiatric Disorders, Vice Chair of Academic Affairs, and Professor of Neurology prior to joining Cleveland Clinic. An active and productive researcher, he has initiated or participated in over 50 clinical trials and has published his findings in well over 300 articles and abstracts on Parkinson’s disease, cervical dystonia, blepharospasm, and other movement disorders. He has nearly 40 published book chapters and books to his credit, and has served on the editorial board of Movement Disorders and is currently an editorial board member of the American Journal of Clinical Neurology, European Neurological Journal, and Clinical Neuropharmacology. Dr Fernandez is also an active member of the Parkinson Study Group (PSG), Dystonia Study Group (DSG), and Huntington Study Group (HSG), American Academy of Neurology (AAN) and its Movement Disorders Section, Movement Disorders Society (MDS), Florida Society of Neurology (FSN) and the World Neurology Foundation (WFNo).
Dr Fernandez is a fellow of the AAN, and a member of the American Neurological Association. He is currently elected as a Councilor for the AAN Movement Disorders Section, Executive Committee Member of the PSG and DSG; and is also an Executive Board Member of the WNFo. He has served as President of the FSN, and is the current Co-Medical Editor of the MDS Web site.
Maura Fisher (CANADA) is a physiotherapist working at the Royal Victoria and Montreal Neurological Hospitals with a passion for the treatment of neurological conditions. She is certified in LSVT BIG, a neuroplasticity-based rehabilitation approach for people with Parkinson’s. She brings the clinical expertise of her physiotherapy skills and her artistry and love of dance together in a specialized dance program for people living with Parkinson’s in Montreal.
Peter Fletcher (UK) is a Consultant Physician in the Department of Old Age Medicine at Gloucestershire Hospitals NHS Foundation Trust. He specialises in Movement Disorders and shares service delivery with colleagues in Old Age Medicine, Neurology and Psychiatry as well as colleagues from nursing and the allied health professions. From a clinical base in Cheltenham he runs clinics on 4 sites across a very rural county. He is a founder member of and educational advisor to the Parkinson’s Academy and has contributed to all Masterclasses from their inception in 2002 to date. He is past Chair of the British Geriatrics Society Movement Disorders Section and president of the Cheltenham branch of Parkinson’s UK. He is the local principal investigator for the PDMED (Pd medicines), PDGEN (Pd genetics) and PDREHAB (Pd rehabilitation) studies and is currently active in the planning and/or recruitment for a further 4 national Pd projects. He is a Senior Lecturer and an Undergraduate Medical Dean at the University of Bristol. He has an MSc in Medical Education and leads for the Medical School on interprofessional learning and personal and professional development in the curriculum. He examines 3rd, 4th and 5th year medical students for the University of Bristol and both Membership and the Diploma of Geriatric Medicine examinations for the Royal College of Physicians of London.
Edward Fon (CANADA) is an Associate Professor in the Department of Neurology & Neurosurgery at McGill University. He is Attending Neurologist at the Montreal Neurological Institute and Hospital and Director of the McGill Parkinson Program, a National Parkinson Foundation Center of Excellence. Dr. Fon is a Clinician-Scientist whose research focuses on the molecular events leading to the degeneration of dopamine neurons in Parkinson's disease. In the past decade, several genes have been identified that cause forms of the disease. He is particularly interested in how these genes come together and interact to cause PD. His work has focused on one of these genes, parkin, which functions as a key enzyme in the main protein degradation pathway in the cell. This pathway utilizes ubiquitin, a protein that can mark target proteins for degradation. Dr. Fon’s lab has been working on understanding the various functions of ubiquitin in the nervous system and on how defects in parkin could lead to Parkinson’s disease. Dr. Fon’s work in this area could provide important clues about the mechanisms of dopamine neuron death in Parkinson’s disease and potentially lead to innovative new therapeutic strategies. His work has been published in several prestigious journals including Nature Cell Biology, Molecular Cell, Neuron and Human Molecular Genetics. Dr. Fon is currently Chair of the Scientific Advisory Board, Parkinson Society Canada. He is a member of the editorial board of the Journal of Biological Chemistry. He has received many awards during the course of his career including the CIHR Clinician-Scientist award, the Prix de Jeune Chercheur Blaise Pascal and the EJLB Foundation Scholar. He is currently a Chercheur-National of the FRQS. Dr. Fon’s research is supported by the Canadian Institutes of Health Research (CIHR), Parkinson Society Canada, and Prionet Canada (NCE).
Le Dr Edward Fon est professeur agrégé au département de neurologie et neurochirurgie de l’Université McGill. Il est neurologue à l’Institut et hôpital neurologiques de Montréal (INM) et Directeur du Programme de Parkinson de McGill, un centre d’excellence de la National Parkinson Foundation. Les travaux de recherche du Dr Fon portent sur les phénomènes moléculaires conduisant à la dégénérescence des neurones dopaminergiques dans la maladie de Parkinson. Au cours de la dernière décennie, plusieurs gènes à la source de certaines formes de cette maladie ont été déterminés. Le Dr Fon s’intéresse particulièrement à un de ces gènes, parkin, qui agit comme une enzyme clé dans la principale voie de dégradation protéique dans la cellule. Cette voie utilise l’ubiquitin, une protéine qui peut marquer des protéines cibles pour la dégradation. Le laboratoire du Dr Fon cherche à comprendre les différentes fonctions de l’ubiquitin dans le système nerveux et comment les anomalies du parkin pourraient entrainer la maladie de Parkinson. Les travaux du Dr Fon pourraient fournir des pistes importantes sur les mécanismes de la mort de neurones dopaminergiques dans la maladie de Parkinson et donner lieu à de nouvelles stratégies thérapeutiques. Ses travaux ont été publiés dans plusieurs revues prestigieuses dont Nature Cell Biology, Molecular Cell, Neuron, EMBO Reports, Current Biology and Human Molecular Genetics. Le Dr Fon est Président du Conseil scientifique de la Société de Parkinson du Canada. Il a reçu de nombreux prix pendant sa carrière, dont celui de clinicien-chercheur des IRSC, de la Fondation EJLB et, plus récemment, celui de Chercheur National de la FQRS. Le Dr Fon fait parti du comité editorial de la revue Journal of Biological Chemistry. Ses travaux bénéficient de subventions des Instituts de recherche en santé du Canada (IRSC), de la Société de Parkinson du Canada et de Prionet Canada.
Susan Fox (CANADA) is Associate Professor Neurology, University of Toronto and Staff Neurologist Movement Disorders Clinic, Toronto Western Hospital, UHN, Canada. She performed her medical and neurological training in Manchester and Liverpool, UK. Appointed Consultant Neurologist, Walton Centre Liverpool 2001-2003. Moved to Canada in 2003 to take up current position. Research interests include preclinical studies of Parkinson’s disease investigating disease mechanisms, particularly neuropsychiatric problems as well as phase II and phase III clinical trials of new treatments for movement disorders. Currently also chair of the Movement Disorder society evidence based medicine update on treatment of motor symptoms for Parkinson’s disease.
Joseph Friedman (USA) is director of the Movement Disorders Program at Butler Hospital and Professor and Chief, Division of Movement Disorders at the Warren Alpert Medical School of Brown University. He has been a member of the Parkinson Study Group since its inception, the clinical director of the RI Parkinson Information and Referral Center of the APDA since 1984. He has served on the editorial board of Movement Disorders and is currently on the editorial board of Parkinsonism and Movement Disorders. His research interests have focussed on behavioral aspects of PD and he wrote the book, Making the Connection Between Brain and Behavior: Coping with Parkinson's Disease, which discusses the many behavioral problems that PD patients and their families cope with.
Thomas Gasser (GERMANY), clinical neurologist, born in 1958, has made significant contributions to the genetics of movement disorders, in particular Parkinson’s Disease. He was one of the first in Germany who combined clinical and molecular genetic expertise in order to map and clone new genes, define genotype-phenotype correlations, explore the functional impact of mutated genes and identify the genetic contribution to common complex neurologic disorders. His major discoveries were that mutations in the gene for epsilon-sarcoglycan (SGCE) cause myoclonus-dystonia, an inherited form of generalized dystonia-plus, and that mutations in the LRRK2 gene, encoding leucine-rich repeat kinase 2, cause the most common form of autosomal dominantly inherited Parkinson’s disease. Together with Dr. Andrew Singleton of the NIH, Bethesda, he was responsible for the first successful genome-wide association study in Parkinson’s disease, establishing the importance of common genetic variability for the etiology of sporadic PD. Gasser is in his second term as a member of the German Research Council and his second term as chairman of the scientific issues committee of the Movement Disorder Society. He has been a two term chairman of the scientist panel of neurogenetics of the European Federation of Neurological Societies and of the working group for neurogenetics of the German Society of Neurology. In 2010, he was elected chairman of the scientific advisory board of the "Joint Programming on Neurodegenerative diseases, in particular Alzheimer’s disease”, a highly visible EU-funded pilot initiative of 27 member states which has been established to formulate a strategic research agenda (SRA) as a basis to direct coordinated funding of research by European national funding agencies in this important area over the next years.
Oscar Gershanik (ARGENTINA) is a Professor and Scientific Director of the Institute of Neuroscience at the Favaloro Foundation University Hospital in Buenos Aires, Argentina. He is also the Director of the Movement Disorder Unit at the same institution and Director of the Laboratory of Experimental Parkinsonism, a basic research laboratory, at the Institute of Pharmacological Research under the jurisdiction of the National Council for Scientific Research and Technology and the University of Buenos Aires, Argentina. Dr. Gershanik received medical training at the University of Buenos Aires where he graduated "Magna Cum Laude”, and did his post-graduate neurology training at the French Hospital in Buenos Aires, under the mentorship of Prof. Alfred Thomson. He completed a Parkinson’s Disease and movement disorders fellowship, at Mount Sinai Hospital in New York under Prof. Melvin Yahr, and later on was invited as Associate Professor of Neurology and Pharmacology, in the Neurology Department of the University of New Jersey Rutgers Medical School under Prof. Roger Duvoisin. His research interests have been focused early on, on the study of dopamine receptors interactions, on trophic mechanisms induced by levodopa therapy in animal models of Parkinson’s disease, and lately on plastic and molecular changes underlying the development of levodopa-induced dyskinesias, and has published extensively on those topics.. Dr. Gershanik is and has always been actively involved in clinical practice in the field of movement disorders; and teaching, both at the undergraduate and post-graduate level, having trained numerous young neurologists, both from Argentina and abroad, in the field of movement disorders. He has lectured extensively both locally and abroad and actively participates at the international level; he has been an officer of The Movement Disorder Society and a member of different committees within that society. He is the Chair of the Clinical Science Subcommittee of the Program Committee of WPC 2013.
Christopher Goetz (USA) is Professor of the Department of Neurological Sciences and Pharmacology at Rush University Medical Center and serves as Director of the Movement Disorders Program supported by the Parkinson’s Disease Foundation. He is a senior Fulbright Scholar and worked for two years at the College de France in Paris. He has served on national and international advisory boards, is an Officer of the Movement Disorder Society, and a member of the American Neurological Association, the American Academy of Neurology, The American Olser Society, and the French Neurological Society. Dr. Goetz has published over 400 peer-reviewed articles, and over 200 book chapters in the field. He has also published and co-authored fourteen books and monographs. He has been co-Editor-in-Chief of Movement Disorders and Editor-in-Chief of Clinical Neuropharmacology. His major interest is the pharmacology and medication therapy of movement disorders, including Parkinson’s disease. He is particularly interested in non-motor aspects of movement disorders, including specifically, hallucinations, cognitive decline, and depression. Further research efforts have focused on scale development for evaluating movement disorders, and he has led the Movement Disorder Society Task Force to develop a new version of the UPDRS, termed the MDS-UPDRS. He has a special interest in placebo effects and how they influence the interpretation of clinical trials in Parkinson's disease and dyskinesia. Dr. Goetz and his team are currently investigating the safety and efficacy of gene therapy in Parkinson’s disease patients and are involved in other studies aimed to prevent the progression of Parkinson’s disease in its early stages. He is an active researcher in the history of neurology and has written extensively with his major research interest being the study of nineteenth century French and U.S. neurology with particular interest in J-M. Charcot and his school.
Victoria Goodwin (UK) graduated from the University of Salford in 1995 as a physiotherapist and worked in full-time clinical practice until 2006, specialising in the community rehabilitation of older people, in particular falls prevention. She was awarded a prestigious Researcher Development Award by the National Institute of Health Research (NIHR) in 2006 to undertake a PhD at the Peninsula Medical School in Exeter to examine the effectiveness of an exercise programme to reduce falls in people with Parkinson’s. She has published work relating to both falls and Parkinson’s, including clinical practice guidelines for physiotherapists. She is the national Research Officer for AGILE (Chartered physiotherapists working with older people), having previously held a number of positions on the national committee since 2003, including Chair. Dr Goodwin is currently a Senior Research Fellow at the University of Exeter Medical School and a physiotherapist with Torbay and Southern Devon Health and Care Trust.
Joyce Gordon (CANADA), President and CEO of Parkinson Society Canada, is building a unified and cohesive movement with sustainable growth in Canada to better serve all individuals living with Parkinson’s. She has more than twenty-five years’ experience working in leadership positions in the not-for-profit, government, hospital, education and corporate sectors with expertise in advocacy and government relations, marketing and communications, programs and services , revenue development, and organizational capacity building. She has served on National Task Forces and on national and international boards. She is a builder of partnerships and collaborations, including leading in the development of Neurological Health Charities Canada. She began her career in kinesiology, health promotion and disease prevention.
Mariella Graziano (LUXEMBOURG) is a member of the European Parkinson Disease Association (EPDA) board since 2003. Since 2000 she has worked closely with the Luxembourg Parkinson's Disease Association and was elected its vice-president in 2008. Mariella is also currently the President of the Association of Physiotherapists in Parkinson's Disease Europe (APPDE) and has produced various teaching materials for people with Parkinson's and their families on behalf of both the APPDE and the EPDA. In addition, she runs workshops throughout Europe and other parts of the world to address the specific mobility difficulties that affect people with Parkinson's. Born in Argentina, Mariella moved to the UK in the 1980s, where she graduated as a physiotherapist. From the early 1990s, she worked as a neuro-physiotherapist at the National Hospital for Neurology and Neurosurgery in London developing a special interest in movement disorders and Parkinson's, moving to Luxembourg in 1997 where she has her own physiotherapy practice.
Mark Guttman (CANADA) is the Director of the Centre for Movement Disorders in Markham, Ontario which is one of the largest Parkinson's practices in the country with over 2000 Parkinson's patients. The Centre for Movement Disorders is a National Parkinson Foundation Centre of Excellence based on its support of clinical and research efforts in Parkinson's disease. Dr. Guttman is involved with Parkinson Society Canada by being a member of the Research Policy Committee and has previously been a member of the Scientific Advisory Board and the National Board. He is also a member of the National Parkinson Foundation Scientific Advisory Board. In addition to performing research in Parkinson's disease and related disorders, he reviews grants for many funding agencies and reviews scientific publications for medical journals.
Ruth Hagestuen (USA) began working with Parkinson's disease in 1987 when she joined the Methodist Hospital Parkinson's Center as nurse coordinator of a multidisciplinary clinic and regional Parkinson’s Center. She eventually assumed the role of program director as the Center evolved and was renamed the Struthers Parkinson's Center. The Struthers Parkinson's Center, designed to provide interdisciplinary, comprehensive care for persons with Parkinson's and their families, is Center of Excellence of the National Parkinson Foundation (NPF). In July of 2000 Ruth joined the NPF staff as National Program Director and Vice President until July 2009. In this position she worked with affiliates nationally and internationally developing strategies to better meet needs of the Parkinson's community through care, outreach and other community initiatives. Two signature programs that were initiated under her leadership are the Allied Team Training for Parkinson's (ATTP) and the National Parkinson Care Network (NPCN). She served as Director of the NYU Parkinson's and Movement Disorders Center from 2009- 2011, working regionally with their interdisciplinary team and collaborative partners to design initiatives informed care, resources and wellness programs accessible at the right time, over time, throughout the course of the living with Parkinson’s disease. Ruth has also rejoined the SPC team working on projects designed to build care strategies and networks that provide access to informed care for people with Parkinson’s and related movement disorders throughout the continuum of care. She also continues to work as consultant to NPF and director of Allied Team Training for Parkinson (ATTP).
Claire Henchcliffe (USA) trained at Oxford University UK, where she completed her doctorate in molecular and cell biology prior to post-doctoral neuroscience research at the University of California at Berkeley. She received her medical degree from the College of Physicians and Surgeons of Columbia University, New York. She completed Neurology residency and Movement Disorders Fellowship at the New York Presbyterian Hospital, under the guidance of Dr Stanley Fahn. After fellowship, she moved to the Weill Medical College of Cornell University, New York, where she established and is Director of the Weill Cornell Parkinson’s Disease and Movement Disorders Institute. She is now Associate Professor of Neurology and Neuroscience. She provides clinical care for patients with movement disorders including Parkinson’s disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, and other conditions. She is a member of numerous medical organizations including the American Academy of Neurology and the Parkinson Study Group. She frequently teaches and writes on Parkinson’s disease, and her team run multiple clinical trials. Her own research interests are in developing new pharmacologic and non-pharmacologic treatments, including exercise based therapy, and the possibility of stem cell therapy, and in biomarker development particularly as applied to trial outcomes.
Etienne Hirsch (FRANCE) is a neurobiologist involved in research on Parkinson’s disease and related disorders. He obtained his PhD in 1988 from the University of Paris VI (Pierre et Marie Curie). He is currently the associate director of CRICM and head of "Experimental therapeutics of Neurodegeneration” at the CRICM at Pitié-Salpêtrière hospital in Paris and councilor for Neuroscience, Neurology and Psychiatry at the French Ministry for higher education and research. He has also been appointed director of the national Institute (ITMO) for neurosciences, cognitive sciences, neurology and psychiatry. His work is aimed at understanding the cause of neuronal degeneration in Parkinson’s disease and is focused on the role of the glial cells, the inflammatory cytokines and apoptosis but also on the consequences of neuronal degeneration in the circuitries downstream to the lesions. He is member of several advisory boards including, French Society for Neuroscience (past-President), Scientific Advisory board at INSERM. He obtained several prizes including Tourette Syndrome Association Award in1986, Young researcher Award, European Society for Neurochemistry in 1990, Grand Prix de l’Académie de Sciences, Prix de la Fondation pour la recherche biomédicale « Prix François Lhermitte » in 1999, Chevalier de l’ordre des palmes académiques in 2009, Prix Raymond et Aimée Mande of the French National academy of Medicine in 2011, Member of the French National Academy of Pharmacy in 2011. He is author of more than 200 peer reviewed articles.
Docteur de l’Université Pierre et Marie Curie-Paris (1988), Etienne HIRSCH est neurobiologiste, directeur de recherche au CNRS, et spécialisé dans la maladie de Parkinson. Il a présidé de 2007 à 2009 le Conseil scientifique de la Fédération pour la recherche sur le cerveau, ainsi que la Société des neurosciences. Il est depuis 2010 le Directeur adjoint du Centre de recherche de l'Institut du cerveau et de la moelle épinière à l'hôpital de la Pitié-Salpêtrière. Il est directeur de l’ITMO Neurosciences, Sciences cognitives, Neurologie et Psychiatrie et chargé de mission au Ministère de l’enseignement supérieur et de la recherche.
Rivka Inzelberg (ISRAEL), born in Istanbul, Turkey in 1959. Studied at the French High School and Medicine at the Istanbul University Medical Faculty. Graduated in 1982 and moved to Israel. Worked as intern in Jerusalem Hadassah Medical School affiliated with the Hebrew University. Neurology resident during 1984-1989 at the Tel-Aviv Sourasky Medical Center. In 1987, started research collaboration with the Department of Applied Mathematics at the Weizmann Institute of Science on kinematics of human movement. After passing the Neurology Boards examination in 1989, worked as senior neurologist at the Tel Aviv Medical Center affiliated with Tel Aviv University, in 1993 in London at the Movement Disorders and Balance Unit at the Hospital for Neurology, Queen Square, studied movement disorders and the excitability of the cortex in Parkinson's disease. Worked as senior neurologist at the Tel-Aviv Medical Center and as senior lecturer in neurology at the Tel-Aviv University until 1996. From 1996 to 2006 served as Director of the Movement Disorders and Memory Clinic in the Hillel Yaffe Medical Center in Hadera, affiliated with the Technion, Rappaport Faculty of Medicine in Haifa. 2006-2007 chaired the department of Neurology at Meir Hospital affiliated with Tel Aviv University, Sackler Faculty of Medicine. She taught Neurology as Associate Professor at the Techinon between 2006-2009. Since 2007, she is a Senior Neurologist at the Department of Neurology, Sagol Neuroscience Center at the Sheba Medical Center and teaches neurology as Associate Professor of Neurology at Tel Aviv University since 2009. She wrote more than 90 peer-reviewed scientific articles, was awarded international research grants including the NIH and the title of excellent university teacher four times. Special research interests are Parkinson's disease, Alzheimer's disease, cognitive functions in Parkinson's disease, cancer and Parkinson's disease, kinematic analysis of movement, other movement disorders such as tremor, dystonia.
Tom Isaacs (UK) was diagnosed with Parkinson's at the young age of 27 and since then has done everything he can to raise funds, heighten awareness and find a cure for the condition which is perceived by many as a condition affecting the elderly alone.
Having completed his highly successful 1,250-mile sponsored walk in 1999, Tom left his job as Director of a London property company in April 2002 to undertake his Coastin' challenge. By April 2003, Tom had walked 4,500 miles around the British coastline, climbed the highest mountains in England, Scotland and Wales and run the Flora London Marathon, raising over £350,000. In 2004 he was runner-up in the GMTV/Daily Mirror Fundraiser of the Year Award and in 2005 he was elected Charity Personality of the Year. A year later he co-founded The Cure Parkinson’s Trust, an organization of which he is President and which has since gone on to raise over £5.5 million and has been involved in funding and facilitating ground breaking research in Parkinson’s.
Tom was a Board Member of the European Parkinson’s Disease Association from 2005 until 2010. He also represents the interests of people with Parkinson’s on DeNDRoN (the Dementias and Neurodegenerative Diseases Research Network). Tom acted as the patient representative on the Steering Committee for the World Parkinson Congress 2010 organizational committee and continues in this role for the 2013 Congress. At the 2010 Congress he made nine presentations to a variety of audiences. He is also a leading contributor to the SENSE-PARK project, which is a European funded initiative to establish a more personalized, objective measuring device for people with Parkinson’s and those who treat them.
Tom has written a book "Shake Well Before Use” about his walk and his experiences with Parkinson’s, which he conveys with passion, optimism and humor. He speaks regularly about his condition and the ability of people with Parkinson’s to inject urgency into progressing the delivery of new therapies to the clinic.
Joseph Jankovic (USA) received his Medical Degree at the University of Arizona, Dr. Jankovic completed medicine internship at Baylor College of Medicine, Houston in 1974. He subsequently completed residency in Neurology at the Neurological Institute, Columbia University, New York City, where he was selected as the Chief Resident. While there he obtained additional training in movement disorders with Stanley Fahn, MD. In 1977 he joined the faculty of Baylor College of Medicine and established the Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC). The PDCMDC has been recognized as a "Center of Excellence" by the National Parkinson Foundation and the Huntington Disease Society of America. Promoted to a full professor of Neurology in 1988, Dr. Jankovic holds the endowed Baylor College of Medicine Distinguished Chair in Movement Disorders.
Dr. Jankovic has published over 700 original articles and chapters and has edited or co-edited 35 books and volumes, including several standard textbooks such as "Neurology in Clinical Practice” (NICP.com) and "Parkinson's Disease and Movement Disorders” (along with a video atlas), both currently in 5 th edition. Dr. Jankovic, along with Dr. Fahn, co-authored a comprehensive book (and DVD) entitled "Principles and Practice of Movement Disorders”, published in 2007.
Beom S. Jeon (SOUTH KOREA) is Chairman of Neurology and Medical Director of the Movement Disorder Center at Seoul National University Hospital. He serves as the International Delegate of the Korean Neurological Association and was the President of the Korean Movement Disorder Society. He is the Director of the Division of the Medical Policy at Seoul National University College of Medicine. Dr. Jeon graduated from Seoul National University College of Medicine, and completed his neurology residency both at Seoul National University Hospital (1983-1987) and at the University of Minnesota (1987-1991), and then had movement disorder fellowship under Dr. Stanley Fahn at Columbia University (1991-1993). He also studied basic neurosciences under Dr. Robert Burke as H. Houston Merritt Fellow (1997-1998) at Columbia University. Dr. Jeon has extensively studied genetics in Korean patients with parkinsonism, and is currently interested in medical and surgical treatment of advanced parkinsonism. He has published over 180 peer reviewed articles, and wrote eight book chapters and three books for patients and families with Parkinson’s disease and ataxia.
Ryuji Kaji (JAPAN) is Professor and Chairman of the Department of Neurology at Tokushima University , Graduate School of Medicine, Tokushima, Japan . H e has been a member of The Movement Disorder Society (MDS) since 199 1 and has served on the MDS Membership and Congress Scientific Program Committee s, as well as on the Editorial Board of Movement Disorders journal.
Dr. Kaji received neurology and neurophysiology training at the University of Pennsylvania and completed a movement disorders training course at the Kyoto University Hospital. His research interests have been focused on the study of pathophysiology, molecular genetics, and functional neuroanatomy of dystonia, especially those of lubag dystonia.
Kenichi Kashihara (JAPAN) is Director of the Department of Neurology at Okayama Kyokuto Hospital, Japan from 2012. Dr. Kashihara was awarded his MD from Okayama University Medical School and his PhD from Okayama University Graduate school, where he studied pharmacological aspect of the central dopaminergic systems. He was a lecturer in the Department of Neurology and Psychiatry at Okayama University Medical school from 1987 to 1994 and lecturer in the Department of Neurology at Okayama University Medical School from 1994 to 2001. From 2001 through 2012, he was served as a head in the Department of Neurology at Okayama Kyokuto Hospital. Dr. Kashihara's main interests are clinical symptoms and pharmacology of Parkinson's disease. He is serving as Secretary of Movement Disorder Society of Japan from 2011.
Regina Katzenschlager (AUSTRIA) is a consultant neurologist and the interim head of the Department of Neurology at Danube Hospital, Social Medical Centre East in Vienna, Austria, as well as head of the Karl Landsteiner Institute for neuro-immunological and neuro-degenerative disorders at Danube Hospital, Vienna.||She trained in neurology and psychiatry in Vienna and did a Fellowship in Movement Disorders with Professor Andrew Lees at the National Hospital for Neurology and Neurosurgery in London, UK. Today, she is involved in clinical||research and teaching with an emphasis on Parkinson’s disease. Dr Katzenschlager is the current President of the Austrian Neurological Society and the Secretary of the Austrian Parkinson Disease Society. She has served on various committees for the Movement Disorder Society as well as on the Editorial Board of Movement Disorders.
Samyra Keus (NETHERLANDS) is project leader for the development of the 1st joint European Physiotherapy Guidelines for Parkinson ’s disease, a joint collaboration of 18 professional Physiotherapy associations. She holds a bachelor’s degree in physiotherapy and a master’s degree in human movement science. In 2010 she gained her PhD in research to physiotherapy for Parkinson’s disease. Previously, she developed the current and only physiotherapy guidelines for Parkinson’s disease. Together with Prof. dr. Bastiaan Bloem, Dr. Marten Munneke and Dr. Maarten Nijkrake, she implemented these guidelines in the Netherlands by developing ParkinsonNet. Next, she co-developed and coordinated the large trial evaluating ParkinsonNet: a large, multi centre trial in which 16 hospitals and 700 patients participated. At the same time she chaired the Dutch national task force developing recommendations for the organization of multidisciplinary Parkinson’s care. Within ParkinsonNet, Samyra is currently responsible for guideline development and implementation.
(USA) received his Ph.D. from the Max Planck Institute for Immuno-biology and the Ludwig Albert University of Freiburg in Germany. He was a post doc under the mentorship of Thomas M Jessell in the Center for Neurobiology and Behavior at Columbia University in New York. From 1999 to 2003 he was the Vice President of Research of the biotech company PsychoGenics, Inc. in New York, which produces and tests murine models of psychiatric and neurological diseases. In 2003 he returned as an independent faculty and principal investigator to the Genome Center of Columbia University. In 2005 his laboratory became a member lab of the newly established Center for Motor Neuron Biology and Disease at Columbia University. In 2012 he became a faculty and principal investigator in the Sophie Davis School of Biomedical Education where his lab is in the research cluster for Neuro-development and repair at the City University of New York.
Anatol Kreitzer (USA) earned his PhD in neurobiology at Harvard University in 2001. He conducted postdoctoral research at Stanford University with Dr. Robert Malenka until 2007, when he established his laboratory at the UCSF-affiliated Gladstone Institutes. Dr. Kreitzer’s laboratory focuses on the function of basal ganglia circuitry in motor control and reinforcement learning. His work integrates a variety of techniques, including electrophysiology, optogenetics, and behavioral analysis. A major goal of his research is to understand the function of synaptic plasticity and neural circuit function in the basal ganglia as it relates to normal learning and pathological conditions, such as Parkinson’s disease and dystonia. He is a recipient of the Pew Scholar Award, the McKnight Scholar Award, and the Society for Neuroscience Young Investigator Award.
Bob Kuhn, JD (CANADA) is the founding
partner of Kuhn LLP, a medium-sized law firm in Vancouver and Abbotsford,
British Columbia, Canada. With over 30 years of experience, Bob is passionate
about serving clients as a trusted problem solver both inside and outside of
the courtroom. He has acted as lead counsel on a number of high profile cases,
including appearing at the Supreme Court of Canada. Bob also gives his
time to charity work, including serving as chair or director of numerous
non-profit entities, as well as writing and speaking.
Bob was diagnosed
with Parkinson's disease in early 2006 at the age of 53. His father died
several years later from complications related tothis cruel disease. It
is Bob's passionate commitment to live positively despite the challenges. He
continues to work full-time in his law practice, write a blog, "Positively
Parkinson's" (www.positivelyparkinsons.com) and speaks on that topic
whenever possible. He has been married to his wife, Renae, for over 37
years, has 3 grown children and takes great joy in his grandson, PJ.
Finally, Bob loves to ride his motorcycle as long and as far as time
permit. He has crossed Canada (ocean to ocean) and back in 2008, ridden
his 2 wheels to touch the 4 corners of the continental United States in 2009,
and traveled all of the Western United States in 2010 and 2011, for a total of
over 50,000 km. He is determined, through writing, speaking and just living
"out loud", to encourage others battling with Parkinson's disease.
Lucie Lachance (CANADA) is a Clinical Nurse Specialist in Movement Disorders at the Montreal Neurological Hospital within McGill University Health Center since 2001. With the McGill Disorders Program Team, she evaluated, delivered and coordinated appropriate care for patients with complex needs and provided support and educational assistance to their families over the continuum of care required by the progressing condition associated with the Parkinson Disease and other movement disorders. One of the leader of the Movement Disorders Program at the MUHC, her activities extend well outside the MUHC as she provide guidance and disseminate best practices to nurses, allied health care professionals and others clinical partners regarding issues related to care and interdisciplinary team effectiveness in the treatment of Parkinson. She is regularly call upon as a lecturer for the Mcgill University Neuro Nursing Program and as invited speaker and organizer at various community lectures and local conferences on Parkinson targeted to the patients, their family and the health care professional. In addition, she is actively promoting an educational networking model for nurses across Canada and the Parkinson Societies at national and international conferences on Movement Disorders. She served the Parkinson Society of Canada as a board member from 2004- 2010 and since 2011. She is now the secretary of PSC. Also was a member for the Parkinson Society Quebec from 2002-2004. Lucie graduated in Nursing from Université de Sherbrooke in 1993, where she also received a M.Sc. in Clinical Science in 1996.
Anne-Louise Lafontaine (CANADA) is the clinical Director of the McGill Movement Disorder Clinic, Montreal, Quebec. She is the director of the Renata Hornstein Parkinson Clinic. She has been a longstanding committee member of the Research Policy Committee for the Parkinson Society Canada. She is the co-chair of the local organizing committee for the World Parkinson Congress 2013.
Anthony Lang (CANADA) is the Director of the Divison of Neurology and the holder of the Jack Clark Chair for Parkinson's Disease Research at the University of Toronto, He is the Director of the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease at the Toronto Western Hospital.
Virginia Lee (USA) is the John H. Ware 3rd Professor in Alzheimer’s Research in the Department of Pathology and Laboratory Medicine. She joined the faculty of the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania in 1981 where she rose to the rank of Professor in 1989. Dr. Lee completed the Executive MBA program at the Wharton School of the University of Pennsylvania (1982-1984), and obtained her MBA degree in 1984. Currently, she is Director of the Center for Neurodegenerative Disease Research and Co-director of the Marian S. Ware Alzheimer Drug Discovery Program at the University of Pennsylvania School of Medicine. Dr. Lee’s research focuses on disease proteins that form pathological inclusions in hereditary and sporadic Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders of aging. Her work was instrumental in demonstrating that tau, α-synuclein and TDP-43 proteins form unique brain aggregates with a central role in numerous neurodegenerative diseases, including Alzheimer’s, Parkinson’s, frontotemporal dementias and amyotrophic lateral sclerosis. She is a member of the Institute of Medicine and her research on Alzheimer’s disease had won her numerous awards.
Christiane Lepage (CANADA) is a family physician with a Master's degree in epidemiology and a Clinical assistant Professor at the Department of Family Medicine, Montreal University. She worked several years in elderly care in Québec and Montréal cities and, in 2009, she joined the Movement Disorders Unit , Centre hospitalier de l'Universitè de Montréal. She is director of the Renata Hornstein Evaluation Centre. This centre offers interdisciplinary care programs for patients with Parkinson disease. Dr Lepage has developed a particular interest in non-motors symptoms and for programs centered on patients' needs.
David Leventhal (USA) is a founding teacher and Program Manager for Dance for PD®, a collaborative program of the Mark Morris Dance Group and Brooklyn Parkinson Group that has now been used as a model for classes in more than 100 communities in eight countries. He leads classes for people with Parkinson's disease around the world and trains other teachers in the Dance for PD approach. Since 2007, he has trained more than 350 teachers in the Dance for PD approach in 18 cities around the world. Along with Olie Westheimer, he is the co-recipient of the 2013 Alan Bonander Humanitarian Award from the Parkinson's Unity Walk. He has written about dance and Parkinson's for such publications as Dance Gazette and Room 217, and has a chapters about the program in two forthcoming books: Multimodal Learning in Communities and Schools (Peter Lang), and Creating Dance: A Traveler's Guide (Hampton Press). He is a frequent guest speaker at Parkinson’s conferences and symposiums, and serves on the Board of Directors of the Global Alliance for Arts and Health. As a dancer, he performed with the Mark Morris Dance Group from 1997-2011, performing principal roles in Mark Morris' The Hard Nut, L'Allegro, il Penseroso ed il Moderato, and Prokofiev's Romeo & Juliet, on Motifs of Shakespeare. He received a 2010 New York Dance and Performance Award (Bessie) for his performing career with Mark Morris. He graduated from Brown University with honors in English Literature.
Renee Le Verrier (USA) is a certified yoga instructor who teaches at Massachusetts General Hospital's Parkinson's Partner Center and at Whittier Rehabilitation Hospital's Neurology Day Program. Renee specializes in creating adaptations and modifications for people living with movement disorders. Her approach to maximizing the benefits and enjoyment of yoga derives from both study and experience. Diagnosed with Parkinson's a decade ago and having survived a childhood stroke, Renee practices yoga to decrease rigidity and fatigue in body as well as increase flexibility and balance in body and in spirit. Renee is the co-director of the APDA Massachusetts Chapter’s Arts & Movement Program and, in partnership with the APDA and TriYoga Boston, she leads a Parkinson's Yoga Teacher Training Certificate Program. She is the author of the book, Yoga for Movement Disorders and its Companion DVD. Renee lives with her husband, son, and an array of pets including her mobility service dog. Renee’s recently released book is A Treasure Hunt for Mama and Me: Helping Children Cope with Parental Illness.
Peter LeWitt (USA) who directs the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital in West Bloomfield, was appointed Professor of Neurology at Wayne State University School of Medicine in 1990. A graduate of Brown University School of Medicine (and also awarded a M.Med.Sc. in Biochemical Pharmacology), his neurology residency training was at Stanford University School of Medicine. His completed fellowship training in experimental therapeutics at the National Institute of Neurological and Communicative Disorders. In addition to conducting clinical trials for Parkinson’s disease and other neurological disorders, his research interests have also included animal models and biomarkers of neurological disease, pharmacokinetic analysis, and gene therapy for Parkinson’s disease. He is the author of more than 300 publications in basic and clinical neuroscience.
Dr. LeWitt was a founding member of the Parkinson Study Group and was elected in 1998 to serve as secretary of the Movement Disorder Society. He is a member of that organization’s Task Force for the Development of Rating Scales for Parkinson’s Disease. Dr. LeWitt has been a recipient or reviewer of research grants from the National Institutes of Health, the Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the U.S.-Israel Bi-National Science Foundation, and other organizations. Since 2003, he has been editor-in-chief of Clinical Neuropharmacology and has served on the editorial boards of Movement Disorders, Journal of Neural Transmission, Journal of Parkinson’s Disease, and Translational Neurodegeneration. Dr. LeWitt has been the mentor for several movement disorder fellowship trainees and has been active in educational programs conducted by the Movement Disorder Society, the American Academy of Neurology, the European Federation of Neurological Sciences, and other organizations.
Irene Litvan (USA) is the Tasch Endowed Chair of Parkinson Disease Research at the University of California San Diego (UCSD), Professor of Neurosciences and Director of the UCSD Movement Disorder Center. She has published more than 230 peer-reviewed articles and chapters on the diagnosis of neurodegenerative parkinsonian and dementia disorders and its neuropsychiatric aspects. She was editor/senior editor of 4 books on atypical parkinsonian disorders and dementias including the first one solely dedicated to progressive supranuclear palsy and first one on corticobasal degeneration. Dr. Litvan is a reviewer for several medical, neurologic and neuropsychologic journals. She mentors master, PhD candidates, medical students, residents and fellows. Dr. Litvan is a fellow of the American Neurological Association and of the American Academy of Neurology. She serves and has served on many boards and committees. She is currently the chair of the MDS Pan American Section Education Committee, secretary of the World Federation of Neurology Research Group on Dementia and member of the medical scientific boards of CurePSP, PSP Europe Association and the Association for Frontotemporal Dementias. She received the National Institutes of Health merit award for leading international multicenter studies to evaluate and improve the clinical diagnostic criteria of several dementia and parkinsonian neurodegenerative disorders. She is the principal investigator of a National Institutes of Aging multisite and multidisciplinary study to identify the genetic and environmental risk factors for progressive supranuclear palsy. The scope of her research is translational in its nature.
Andres Lozano (CANADA) is the Professor and Chairman of Neurosurgery at the University of Toronto and holds both the RR Tasker Chair in Functional Neurosurgery and a Tier 1 Canada Research Chair in Neuroscience.
He is best known for his work in Deep Brain Stimulation (DBS). His team has mapped out cortical and subcortical structures in the human brain and have pioneered applications of DBS for various disorders including Parkinson’s disease, depression, dystonia, anorexia, Huntington’s and Alzheimer’s disease.Dr. Lozano has over 400 publications, serves on the board of several international organizations and is a founding member of the scientific advisory board of the Michael J Fox Foundation. He has received a number of awards including the Olivecrona medal and the Pioneer in Medicine award, has been elected a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences and has received the Order of Spain.
Margarita Makoutonina (AUSTRALIA) is a qualified Occupational Therapist with Masters in Education and a
nursing background. Margarita is an expert in establishing specialized
Multidisciplinary Movement Disorders programs. Ms Makoutonina is the
founding director of ParkiLife Australia Pty Ltd, the Australasian
Ambassador for the World Parkinson Coalition (WPC) and an active
participant in the international multidisciplinary Movement Disorders
network. She is one of the leading members of the Health Professionals
Interest Group of the Movement Disorders Society where she has been
actively involved in developing and launching the website for Health
Professionals. Margarita is a Member of Scientific Committees and the
faculty member for the MDS, WPC and MDPD Congresses. She has been an
instigator for the inclusion of Health Professionals in Scientific
Committees, as well as a section of the Scientific Program devoted to
the Health Professionals at International Congresses. Margarita
presented numerous research papers on the holistic/interdisciplinary
rehabilitative approach for People with Parkinson’s disease nationally
and internationally. She has several publications in the field of
Parkinson’s and developed/conducted lectures, workshops and specialist
training for health professionals, People with Parkinson’s and their
carers (online and facilitated). The Central Executive Committee of
World Parkinson's Education Program has recently honoured Margarita for
her passion, commitment and contribution in the Parkinson’s community
with the Dr. Rana International Parkinson's Community Service Award and
nominated her as a Member of the Education and Development Committee of
World Parkinson's Education Program.
Lisa Mann (USA) is the Education Director and Team Care Coordinator for the OHSU Parkinson Center of Oregon. Lisa earned her Nursing degree from John Hopkins University School of Nursing in 2003. Prior to this she worked in business administration and also taught college history.
Her position includes coordinating the operations of the Movement Disorders clinic, providing integrated support to patients and families, facilitating interdisciplinary care in the clinic and implementing community education and outreach programs for patients, families and health care professionals.
Connie Marras (CANADA) trained in neurology at the University of Toronto, followed by a movement disorder fellowship at the Toronto Western Hospital. Research training includes a PhD in epidemiology at the University of Toronto and further training in epidemiologic research methods at the Parkinson’s Institute in California. She is currently an Assistant Professor of Neurology at the University of Toronto and a movement disorders neurologist at the Toronto Western Hospital Movement Disorders Centre. She cares for patients with all varieties of movement disorders. Areas of research focus are the epidemiology of ‘genetic’ forms of movement disorders, prognosis and environmental etiology of movement disorders and evaluating clinical assessment tools (e.g. rating scales for movement disorders).
Laura Marsh (USA), is the Executive Director of the Mental Health Care Line at the Michael E. DeBakey Veterans Affairs Medical Center Professor and a Professor in the Departments of Psychiatry and Neurology at Baylor College of Medicine in Houston, TX. A geriatric psychiatrist who focuses on psychiatric disturbances in patients with neurological disorders, her research focuses on improving the characterization, detection, and treatment of Parkinson's disease-related psychiatric disturbances. Dr. Marsh graduated from Ohio State University College of Medicine in Columbus, OH, USA and psychiatry residency training at Johns Hopkins University School of Medicine in Baltimore, MD, USA and the Institute of Psychiatry in London, England. She completed research fellowships in brain neuroimaging and neuropsychiatric disorders at the National Institute of Mental Health and at Stanford University School of Medicine and was a member of the Stanford faculty from 1994 until 1998. In 1998, she returned to Baltimore as a faculty member at Johns Hopkins. There, Dr. Marsh was director and principal investigator of the Clinical Research Program of the NIH-funded Morris K. Udall Parkinson's Disease Research Center and developed independent clinical and research programs focused on neuropsychiatric disturbances in Parkinson's disease. In 2009, she joined the faculty at Baylor College of Medicine, where her research on Parkinson's focuses on strategies to integrate psychiatric and mental health care with other medical specialties. Dr. Marsh serves on the advisory boards for the American Parkinson's Disease Association, the National Parkinson Foundation, and the Houston Area Parkinson's Society and is chair of the Program Committee for the Parkinson's Study Group.
Soania Mathur (CANADA) is a family physician living outside of Toronto, Ontario who had to resign her practice as a result of her Young Onset Parkinson's Disease a full twelve years after her diagnosis at age 27. Now she is a dedicated speaker, writer, educator and Parkinson's advocate. She speaks passionately about the challenges of adjusting physically and emotionally and the coping strategies available to patients. Dr. Mathur is an active speaker for the Parkinson’s Society of Canada at patient-directed conferences and also serves as a resource for education projects. She works with The Michael J. Fox foundation for Parkinson’s Research and serves on their Patient Council. She is a member of The Brian Grant Foundation Advisory Board that helps to create educational programming. She is the founder of Designing A Cure Inc. (www.designingacure.com) which was initially created to raise funds directed towards research and awareness of Parkinson's Disease and now serves as a platform to educate and inspire those living with this disease to take charge of their lives, to live well with Parkinson's. Dr. Mathur has a special interest in helping educate the youngest affected by the stress of this chronic disease. To help facilitate dialogue between children and their loved ones, she has authored two books: "My Shaky Grandpa” and "Shaky Hands, Loving Hands – A Children’s Guide To Parkinson’s Disease”. Recently, Dr. Mathur launched a new company Hippylicious (www.myhippylicious.com) which is dedicated to providing parents with all natural, non-toxic personal care products for their families in an effort to reduce their toxin load, a factor that she believes is significant in the development or exacerbation of many diseases. Most importantly, she is the proud mother of three beautiful daughters and married to her loving and supportive husband Arun, a Urologic suregeon.
Heidi McBride (CANADA) is a graduate of McGill (B.Sc ’91, Ph.D ’96) and completed her post-doctoral training at the EMBL in Heidelberg, Germany in 2000. She spent her years as a trainee in the fields of mitochondrial protein import and the molecular mechanisms of endocytosis, Rab activation and SNARE assembly. Within her own lab over the past decade, she has made numerous discoveries into the fundamental behaviour of the mitochondria and how they are integrated into the cellular environment. After 11 years at the University of Ottawa Heart Institute, she relocated her lab to McGill University (June 2011). As an Associate Professor in the Department of Neurology and Neurosurgery, she is engaged in training undergraduates, grad students and post-doctoral fellows. With a highly collaborative spirit, she joined the Neuromuscular Group at the Montreal Neurological Institute where she will help to create a dynamic, multidisciplinary team to tackle the complex problems of neurodegenerative diseases like ALS, Parkinsons, Huntingtons and various forms of Ataxias.
Patrick McGowan (CANADA) is a Professor in the School of Public Health and Social Policy at the University of Victoria. Between 1992 and 2002 he was the Assistant Director of the Institute of Health Promotion Research at the University of British Columbia, and an Adjunct Professor in the Department of Health Care and Epidemiology. Dr. McGowan’s research career over the last 25 years has mainly focused on several aspects of health education programs for persons experiencing chronic health conditions, especially self-management programs and strategies. He has been implementing and researching the feasibility and effectiveness of self-management programs relating to particular chronic health conditions such as: diabetes, arthritis, osteoarthritis, and tuberculosis. This research is being conducted at the community level (including ethnic and aboriginal communities), and at provincial, national, and international levels. In addition to communiuty self-management programs Dr. McGowan teaches self-management support strategies to health care professionals and is involved investigating strategies to get self-management support strategies integrated into clinical settings.
Janis Miyasaki (CANADA) is the Associate Clinical Director of the Toronto Western Hospital Movement Disorders Centre at the University of Toronto. She developed the first interdisciplinary palliative care program for Parkinson's disease and related disorders in 2007 and has published the first evidence for efficacy in this population. She completed her training at the University of Toronto in 1992 and a fellowship in Movement Disorders under Dr. Anthony Lang in 1994. Dr. Miyasaki has authored evidence-based guidelines on Parkinson's disease and other movement disorders and created an online tool for primary care practitioners treating PWP.
Linda Morgan (USA) diagnosed with Parkinson’s disease in 2005; within 35 days of diagnosis, Ms Morgan had researched and founded the first clinical trial in which she was to participate, the beginning of her work in clinical research advocacy. Since then she has participated in more than 17 trials varying from a blood draw and exam to a weeklong inpatient trial at the National Institutes of Health (NIH). Currently, Ms Morgan is a Research advocate with Parkinson’s Disease Foundation’s Parkinson’s Advocates in Research (PAIR) program, having graduated from the inaugural Clinical Research Learning Institute (CRLI) in 2008. As an advocate for participation in clinical trials, she has spoken on the subject at regional and national as well as local Parkinson’s disease venues. On the same subject, she has been quoted in Time Magazine as well as the Wall Street Journal. Morgan currently serves on the PDF’s Parkinson Patients Advisory Council, served on the program planning committee of the 2012 Southeastern Parkinson Disease Conference as well as the planning committee for this World Parkinson’s Congress. She has been very involved with the newly formed Patient Centered Outcomes Research Institute (PCORI) in the USA having served on the Research Prioritization Technical Working Group to provide the patient perspective on the approach, process, and tools for topic prioritization and currently as a project reviewer for PCORI. Ms Morgan is a Registered pharmacist, currently working part-time as a remote clinical pharmacist for Mission Hospitals, Asheville, NC. Graduated with a Bachelor of Science in Pharmacy from the University of North Carolina at Chapel Hill and later earned her Master in Business Administration.
Margaret Mullarney (IRELAND) was diagnosed with Parkinson’s in January 2004 when she was 47 years old. Since being diagnosed, Mags has been researching and educating herself to better understand Parkinson’s and to improve her quality of life through taking a multidisciplinary , self management participatory approach. Mags has realized the benefits of regular exercise and good nutrition and has developed a 5 elements model of care to support the self management . She is a solicitor by profession and a Life and Business coach. She is the founder of Move4Parkinson’s which is a charity set up to empower and inspire people with Parkinson’s to have a better quality of life.
Alice Nieuwboer (BELGIUM) is working as a professor at the Faculty of Movement and Rehabilitation Sciences of the Katholieke Universiteit Leuven (Belgium), teaching both undergraduate and postgraduate physiotherapy students in specialised topics in neurological rehabilitation and evidence-based physiotherapy. She was principal investigator of the EU-funded RESCUE-project (2002-2005) on cueing in Parkinson’s disease (PD) and has published widely on several topics in the field of neurological rehabilitation. Her main research efforts are dedicated to the mechanisms of freezing of gait, cueing and rehabilitation in movement disorders. Since 2007, she is running several research programs involving gait analysis of turning, prospective study of freezing and brain imaging of upper limb freezing, motor learning of writing problem, motor imagery and dual tasking in PD. She is involved in 2 7th framework EU-funded projects V-time and CUPID.
Jose Obeso (SPAIN) is Full Professor and Consultant of Neurology in the School of Medicine and the University Hospital (Clínica Universitaria), and Senior Investigator in the Center for Applied Medical Research, University of Navarra, Pamplona, Spain.España. He graduated from the University of Navarra in 1976 and specialized in neurology and neurophysiology in San Sebastian and Pamplona, Spain. From 1980 to 1982 he worked as a researcher in movement disorders under the supervision of Professor C. David Marsden in London (UK), which proved to be the most exciting and decisive period in his career. In the University of Navarra, in Pamplona, and for a short period of time in Tenerife (Spain), Dr. Obeso has devoted his efforts to the care of patients with movement disorders, particularly Parkinson’s disease, and to clinical and laboratory research. Together with Tom Chase and Fabriccio Stochi, he pioneered the concept of "Continual Dopaminergic Stimulation” for treating Parkinson’s disease, and has played a major role in the recent renewal of interest in surgical treatment for Parkinson’s disease. He has published over 300 original research papers and 90 review articles, has edited 18 books and special issues of medical journals, and has contributed 98 book chapters. The main subjects of these publications are the pathophysiology and treatment of myoclonus and dystonia, the origin and treatment of dyskinesias in Parkinson’s disease, the pathophysiology of the ganglia, experimental models of Parkinson’s disease and the surgical treatment of Parkinson’s disease. He currently has a Hirsch index of 61. He is Chief Co-Editor of the Movement Disorders Journal since 2010. His main research interest at the moment focuses on defining the factors and characteristics that make dopaminergic neurons specially vulnerable in Parkinson’s disease, with a view to finding treatment that can delay the progress of this neurodegenerative disease.
Michael Okun (USA) is the Adelaide Lackner Professor of Neurology at the University of Florida, and the Administrative Director and co-founder of the UF Center for Movement Disorders and Neurorestoration. Dr. Okun completed his M.D. degree and his neurology residency training at the University of Florida where he graduated with Honors. He completed his fellowship training in movement disorders at Emory University. Currently the center he directs has 45 interdisciplinary faculty members dedicated to care, outreach, education and research for Parkinson’s disease and movement disorders. He serves as the National Medical Director for the National Parkinson Foundation and administrates the NPF Ask the Expert web-forums. He co-chairs the Medical Advisory Board for the Tourette Syndrome Association. Dr. Okun’s research has explored motor and non-motor basal ganglia brain disorders and deep brain stimulation. He has published over 250 peer-reviewed papers exploring cognitive, behavioral, and mood effects of basal ganglia disorders. His newest book on Parkinson's disease has been translated into over 20 languages- Parkinson's Treatment: 10 Secrets to a Happier Life.
Michel Panisset (CANADA) is currently Professor of Medicine at the Université de Montréal, associate member at the Montréal Neurological Hospital and head of Neurology at CHUM. He is co-Director of the André-Barbeau Movement Disorders Clinic of CHUM and co-director of the McGill-University of Montréal Movement disorder functional surgery program. Dr Panisset and his team care for near 5000 patients with Parkinson disease and other movement disorders and the surgical program has allowed near 250 patients to receive deep brain stimulation.
He received his MD degree from the Université de Montréal and trained in neurology at the University of Pittsburgh, Pennsylvania. He further specialized in movement disorders and dementia at INSERM, Paris, France and then at McGill University, Montréal. He obtained a Diplôme d'Études Approfondies (DEA) in neuropsyhology at the Université Claude Bernard in Lyon, France.
Stephane Palfi (FRANCE) is a Professor of Neurosurgery and Division Head of the Translational Experimental Therapeutics program in Functionnal Neurosurgery at Henri Mondor Medical center, Paris University (UPEC). His interests are in developmental therapeutics for Parkinson disease, Huntington disease, Tremor, Dystonia, Psychiatric disorders. He has worked extensively in the area of electrical neuromodulation of the brain in movement disorders, gene therapy for Parkinson disease, cell grafting for Huntington and Parkinson disease as well as primate models of neurodegenerative disorders. Pr. Stéphane Palfi has published extensively on trophic factor and enzymes based gene therapy in Parkinson disease and Huntington disease. He is a principal investigator on numerous preclinical and clinical studies and has been involved in studies of many novel agents including implanted brain devices, trophic factors GDNF, CNTF and Lentiviral vectors encoding for dopamine biosynthesis enzymes.
Rajesh Pahwa (USA) is Professor in the Department of Neurology and Director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas School of Medicine in Kansas City.
Upon attainment of his MBBS (MD) degree at Seth G.S. Medical College, University of Bombay, India, Dr Pahwa completed an internship in medicine at Baylor College of Medicine followed by a residency in Neurology at Baylor College of Medicine, Houston, Texas. He then completed a one year fellowship in movement disorders at the University of Kansas Medical Center before joining the faculty of the Department of Neurology as an Instructor in 1992.
Dr Pahwa is a Diplomate of the American Board of Psychiatry and Neurology. His research interests are centered around the various aspects of Parkinson’s disease and essential tremor. He is currently involved in various studies related to medical and surgical forms of therapies for Parkinson’s disease and essential tremor. Dr Pahwa has published over 100 peer-reviewed articles. In addition he has published numerous chapters and abstracts in leading neurology and movement disorder journals. He has conducted over 50 clinical trials related to Parkinson’s disease and other movement disorders. He is the co-editor of "Handbook of Parkinson’s Disease,” 3rd , 4th and 5th editions, "Therapy of Parkinson's Disease," 3rd edition, "Handbook of Essential Tremor and other Tremor Disorders,” 1st edition, and co-author of the book "Parkinson’s Disease: Questions and Answers,” 4th edition. He is also the Co-Editor in Chief of the International Journal of Neuroscience. He is also an active member of American Academy of Neurology, American Neurological Association, Movement Disorder Society, Kansas City Neurology Neurosurgery Society, Parkinson Study Group, and Tremor Research Group.
Malin Parmar (SWEDEN) is an expert on differentiation and maturation of human pluripotent and multipotent stem cells as well as on the quickly growing field of reprogramming. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be reprogrammed into neurons by expressing a few transcription factors and how dopamine neurons can be generated from human embryonic stem cells.. Malin Parmar collaborates with several European consortia including NeuroStemcell and Transeuro and has recently been awarded a starting grant from the European Research Council.
Nicola Pavese (UK) is a Clinical Senior Lecturer and Consultant Neurologist based at Imperial College London. He is also Associate Professor in the Department of Clinical Medicine (Center for Functionally Integrative Neuroscience) at Aarhus University. He achieved Specialist qualification in Neurology in 1994 and Specialist qualification in Biochemistry and Clinical Chemistry in1998. He also has a PhD in Neuroimaging and Movement Disorders. His research activity has been focused on neuropharmacology and neurochemistry of movement disorders. He is currently investigating pathogenetic mechanisms underlying non-motor symptoms of Parkinson’s disease by using functional imaging techniques.
Haydeh Payami (USA) is a Senior Research Scientist at New York State Department of Health Wadsworth Center and Professor of Molecular Genetics at State University of New York at Albany. She received her doctorate degree in Genetics from the University of California at Berkeley, where she studied the genetics of complex diseases. Her postdoctoral work, also at Berkeley, focused on how best to integrate genetics with epidemiology in order to study disorders that involve both genetic and environmental factors. She has employed this approach for the past 25 years to study Alzheimer’s disease, Parkinson’s disease and healthy aging. Her lab recently pioneered genome-wide gene-environment interaction studies that led directly to identification, for the first time, of genes that modify the protective effects of caffeine and nicotine against PD.
Leonard Petrucelli (USA) is Chair and Professor in the Department of Neuroscience at Mayo Clinic in Florida. Dr. Petrucelli’s major research goal is to identify the processes underlying neurodegeneration in Alzheimer’s, Parkinson’s and Lou Gehrig’s (ALS) disease-related disorders. His studies are focused on unraveling the role of the ubiquitin proteasome and chaperone system and devising therapies to hamper the processes that cause neuronal death. Using cell and animal models, his team aims to gain insight into the processes that initiate the abnormal, toxic aggregation of certain proteins, such as tau and TDP-43, and the harmful consequences. Dr. Petrucelli, who earned his Ph.D. in molecular and cellular biochemistry at Loyola University and Stritch School of Medicine, Chicago, is principal investigator for several grants funded by the National Institutes of Health and Department of Defense. Dr. Petrucelli’s team has been on the forefront of neurodegenerative disease research. He has published dozens of articles, editorials, and book chapters in peer-reviewed journals such as Nature Medicine, The Proceedings of the National Academy of Sciences U S A, Journal of Clinical Investigation, Journal of Neuroscience and Neuron. Dr. Petrucelli has received the prestigious National Research Service Award from the National Institutes of Health (NIH); serves on numerous editorial boards, including Journal of Neuroscience; and he also is a member of the Alzheimer’s Forum Scientific Advisory Board. His NIH service includes serving as an invited member of the Cellular and Molecular Biology of Neurodegeneration (CMND) Study Section.
Philippens (NETHERLANDS) is an expert on neuroprotection in non-human primates. She is head of the division Neuropathology at the Biomedical Primate Research Centre (BPRC) that is focussed on Parkinson’s disease research ranging from proteomics, immunology, brain imaging, (neuro)physiology, to extensive behavioral methods. The BPRC is a non-profit scientific research institute for biomedical research that requires experimental primate models in order to contribute to the identification and development of new medicines. For her research she received grants from the EU transnational access to the research infrastructure PRIMOCID of EUPRIM-Net of the 6th Framework Program for PD related research, the Dutch ministry of Defence on Sleep and Alertness and on Post Traumatic Stress Syndrome and US Army Grant Agreements for neuroprotection against neurodegeneration (W81XH-05-1-0517) and participated in a major US Army Cooperative Agreement on the Golf War Syndrome (DAMD17-97-1-7360).
Barbara Picconi (ITALY): Since the beginning of her scientific career in Neuroscience in the group of Prof. Calabresi, Barbara has started to focus her interest on behavioural and synaptic||aspects of experimental models of Parkinson’s Disease, by lesioning the ascending nigrostriatal dopamine (DA) pathway with the 6-OHDA toxin that mimic parkinsonian pathology and, then, characterizing the synaptic plasticity changes in the corticostriatal pathway. Over the years of her Ph.D. training, Barbara started to study the alterations occurring in the corticostriatal synaptic transmission after DA denervation in this useful experimental model of PD. During her Ph.D., she had the chance to spend few months at the Laboratory of Neurobiology, in Wallenberg Centre (Sweden) directed by Prof. Cenci-Nilsson, who is an expert in a model of L-DOPA-induced dyskinesia in rodents. Therefore Barbara has focused on behavioural aspects of experimental models of PD and dyskinesia. She soon started to characterize the electrophysiological plastic changes associated to dyskinesia occurrence in 6-OHDA-lesioned rats, chronically treated with L-DOPA. Advances in the experimental approach to the behavioural classification of dyskinetic movements led her to the observation that, based on individual variability, around a 50% of 6-OHDA-lesioned animals treated with L-DOPA developed dyskinesia, the other animals were showing the therapeutic effect of L-DOPA without undesired side effects. Electrophysiological investigations of the mechanisms underlying the functional diversity of these two conditions brought to the characterization of a new form of synaptic plasticity, called depotentiation, which is expressed by healthy striatal cells and striatal cells||in which dopaminergic tone is rescued by L-DOPA treatment but is absent in dyskinetic animals (Picconi et al., 2003). Since 2002 she is focusing on synaptic plasticity in corticostriatal synapses of dyskinetic and non dyskinetic animals in order to get insights on the mechanisms underlying the different responses to||L-DOPA and find a scientific basis for a new therapeutic strategy in PD.
Ron Postuma (CANADA) is Associate Professor of Neurology at McGill University. He graduated from Medicine at the University of Manitoba, did a Neurology residency and epidemiology Masters degree at McGill, and then competed a Movement Disorders Fellowship in Toronto. He is a clinical movement disorders specialist, and has research interests in non-motor aspects of Parkinson's disease, sleep disorders in Parkinson's disease, clinical trials for non-motor and motor aspects of disease, and identification of preclinical / prodromal stages of disease.
Przedborski (USA) is the Page and William Black Professor of Neurology. He holds a joint appointment in the Departments of Neurology, Pathology and Cell Biology and is the Co-Director of the Center for Motor Neuron Biology and Disease and a faculty member of the Center for Parkinson's disease (PD) and Other Movement Disorders at Columbia University. Dr. Przedborski attended medical school at the Université Libre de Bruxelles (ULB), Belgium, and did his internship and residency in Neurology and Psychiatry at the ULB-Erasme Academic Medical Center, Belgium. He then did a fellowship in movement disorders with Dr. Stanley Fahn at Columbia University, where he became Assistant Professor of Neurology in 1991. The research conducted in Dr. Przedborski's laboratory is geared toward unraveling the molecular basis of neurodegeneration and devising therapeutic strategies to hamper the processes that cause neuronal death, the source of many debilitating disorders. In keeping with this goal, to what extent and by which mechanisms do cell-autonomous and non-cell autonomous deleterious processes contribute to the demise of specific subpopulation of neurons in neurodegenerative disorders, such as PD represent a main line of research in his laboratory. These research efforts are supported by federal grants from both NIH and the DoD and by private agencies including the Parkinson's Disease Foundation, the Thomas Hartman Foundation, and MDA's Wings Over Wall Street. Dr. Przedborski is a Senior Editor for the Journal of Neuroscience and an Associate Editor of Movement Disorders.
Pamela Quinn (USA) danced professionally for 20 years with ODC/San Francisco and with actor/writer Michael O’Connor before she was diagnosed with Parkinson’s Disease in 1996. Since that time she has used her extensive movement background, along with her personal experience of the disease, to investigate and create movement therapy for people with Parkinson’s. In addition to her private practice and work as a consultant, she teaches classes for people with Parkinson’s for the Brooklyn Parkinson Group (for whom she created Movement Lab) and for New York University’s PD Wellness program at the JCC. She has been a guest teacher and speaker around the U. S., including at the University of Pennsylvania, the University of Maryland where she helped to plan a conference on self-efficacy for PD patients, and for the Houston Area Parkinson’s Society where she was the keynote speaker. She was the subject of profiles on the CBS Evening News, and on WABC in New York. Dance Magazine asked her to write a feature on her experience as a dancer who developed a life-altering movement disorder, and Neurology Now published her article outlining the benefits of dance in PD therapy. In 2010 she was asked to moderate a panel on "How to Take Charge of Your Parkinson’s” and to teach a class at the Second World Parkinson Congress. Her video, Welcome to our World, was also co-winner of the Congress’s first prize. She is a graduate of both the Applied Teacher Training Program and of PDF’s CRLI program. This past year she was a consultant on Parkinson’s for the film A Late Quartet, both for writer-director Yaron Zilberman and actor Christopher Walken. She lives in Manhattan with her husband and two children.
Remi Quirion (CANADA) is the inaugural Chief Scientist of Quebec since July 1st, 2011. A McGill Full Professor, Psychiatry and outgoing Scientific Director at the Douglas Mental Health University Institute. He served as Vice-Dean, Faculty of Medicine at McGill University, as well as Senior University Advisor (Health Sciences Research) in addition to being the CIHR Executive Director, for Alzheimer's Diseases, from 2009 to 2011.
Under his leadership, the Douglas Research Centre became a premier research facility in Canada in the fields of neurosciences and mental health. Prof. Quirion promoted the development of neurosciences and clinical research in Neurology and Psychiatry as well as social and evaluation aspects of research in mental health and addiction. His research interests include: a) understanding the relationships between key phenotypes of the Alzheimer's brain and b) molecular and pharmacological features of neuropeptide receptors focusing on NPY and CGRP, and their role in memory, pain and drug dependence, and in animal models of schizophrenia. He trained over 20 PhD students and 50 PDF. In addition to being on the Advisory Board of over 15 journals in Psychiatry, Pharmacology, and Neurosciences, he has published 5 books, more than 650 scientific papers and articles, and over 25,000 citations and h index of 78.
Prof. Quirion was the inaugural Scientific Director of the Institute of Neurosciences, Mental Health and Addiction (INMHA) until March 2009. He received many awards and recognitions as: the Médaille de l’Assemblée nationale du Québec”; Fellow of the Royal Society of Canada; "Chevalier” of the "Ordre national du Québec”;"Wilder-Penfield Award”; the Dr. Mary V. Seeman Award and was appointed Fellow of the Canadian Academy of Health Sciences. In 2007 Prof. Quirion became a Member of the Order of Canada (O.C.).
Rémi Quirion est le premier Scientifique en chef du Québec depuis le 1er juillet 2011. Professeur titulaire en psychiatrie à l’Université McGill, il a été directeur scientifique au Centre de recherche - Institut universitaire en santé mentale Douglas; Vice-doyen de la Faculté de médecine de l’Université McGill, et son Conseiller principal (recherche en sciences de la santé); Directeur exécutif de la Stratégie internationale de recherche concertée sur la maladie d’Alzheimer des IRSC de 2009 à 2011.
Sous sa direction, le Douglas est devenu un établissement de recherche de premier rang au Canada. Il a favorisé le développement des neurosciences et de la recherche clinique en neurologie et en psychiatrie, les aspects sociaux de la maladie et l'évaluation de la recherche en santé mentale et en toxicomanie. Ses domaines de recherches sont: a) la compréhension des relations entre les phénotypes clés du cerveau atteint d'Alzheimer et b) les caractéristiques moléculaires et pharmacologiques des récepteurs neuropeptides en particulier le NPY et le CGRP, et c) le développement de modèles animaux de la schizophrénie. Il a formé plus de 20 étudiants au doctorat et 50 au post doctorat. En plus de siéger au conseil consultatif de plus de 15 revues scientifiques, il a publié cinq ouvrages et plus de 650 articles scientifiques.
Le Prof. Quirion a été le premier directeur scientifique de l'Institut des neurosciences, de la santé mentale et des toxicomanies. Parmi ses nombreux prix et reconnaissances, citons: membre de la Société royale du Canada et Chevalier de l'Ordre national du Québec;Chevalier de l’Ordre national du Québec, la Médaille de l'Assemblée nationale du Québec;les prix Wilder-Penfield du Québec celui de la DreMary V.Seeman. En février 2007 il a reçu la distinction d’officier de l’Ordre du Canada.
Lorraine Ramig (USA) is a Professor in the Department of Speech-Language and
Hearing Science at the University of Colorado-Boulder, a Senior Scientist at
the National Center for Voice and Speech-Denver, an Adjunct Professor at Columbia
University in New York City and Co-founder and President of LSVT Global, Inc. She
received her Ph.D. from Purdue University and is an internationally recognized clinical
scientist with an established research record in the areas of aged and
neurological voice disorders. Her research has been funded by the National
Institutes of Health (NIH) for over twenty years. She has lead teams of researchers and clinicians through the process of developing a
voice intervention for PD (LSVT LOUD),
initial studies of its efficacy, describing the underlying physiologic and
neural bases accompanying intervention, and developing technologies to scale
patient accessibility to intervention. The work of these teams has contributed substantially to the knowledge base on speech and
voice in PD, making an impact on the neurology,
otolaryngology and speech communities, improving patient care globally and as
such has positioned speech intervention within the forefront of
rehabilitation science research today. Dr. Ramig
has been a member the National Advisory Council for the National Institutes of
Health-National Institutes of Deafness and Communication Disorders (NIH-NIDCD)
and has received a number of awards including the Honors of the American Speech
Language Hearing Association, the highest award of her professional
Olivier Rascol (FRANCE) is Professor of Clinical Pharmacology and Neuropharmacolgy in Toulouse University Hospital since 1993. He obtained his MD in Neurology (Toulouse, 1985) and his PhD in Neurosciences (Paris, 1992). Dr Rascol is running the Toulouse Clinical Research Centre since 1994 and the Toulouse European Space Clinic since 1998. He is running a Research Group on Motricity in the Research Unit INSERM U825 and is head of the French Reference Center for Multiple System Atrophy (Atypical Parkinsonism) since 2006.
As a neuropharmacologist, Dr Rascol’s main fields of interest are Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. Dr Rascol is currently running several research programs on neuroprotection, new dopaminergic and non-dopaminergic antiparkinsonian medications in collaboration with several research centres in the US and in Europe. He is acting in this field as an external advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies.
Dr. Rascol is member of several international neurological and pharmacological societies. He is a member of the MDS Educational Committee, of the WFN Research Committee on Parkinsonism and Related Disorders and of the MDS EBM and Rating Scales Taskforces. Dr. Rascol is working as associate-editor for the Journal of Neural Transmission and is a member of the editorial board of the Lancet Neurology, and the European Journal of Neurology.
Dr. Rascol has published 300 articles in International Scientific journals (New England Journal of Medicine, Lancet, Annals of neurology, Neurology, Archives of neurology, Brain, Movement Disorders…). He has also been invited to give more than 250 lectures in various European, North and South American and Asian universities or national and international meetings.
Sara Riggare (SWEDEN) is an engineer by training and an unusually engaged patient. She experienced the first symptoms of Parkinson's disease around 1984, when she was in her early teens and has been working with a number of patient organizations during the last decade. In 2010 Sara decided to bring her engineering skills and personal interest in technology and social media into the healthcare field and therefore entered the international master program in Health Informatics at Karolinska Institutet in Stockholm, Sweden. She is currently a doctoral student at the Medical Management Center, and the focus for her research is to investigate if personal health data collected by patients in a systematic way can be useful for the patient, for other patients, for healthcare and research. Sara is also a co-founder of Parkinson's Movement.
Angela Robb (USA) is a Parkinson's disease (PD) carepartner and Reiki Master who shares and teaches the value of Reiki (ray-key) to the Parkinson's community. In 2008, she and her husband Karl developed a Reiki workshop for people with Parkinson's and their caregivers/carepartners . Reiki is a complementary therapy that can help anyone to help themselves to reduce stress, improve self-care, and improve mind, body, spirit and emotional balance.
Angela also speaks & writes about carepartner issues affecting herself and the caregiver/carepartner community. She has spoken at the NPF Young Onset Parkinson Network conferences, regional PD conferences, The Victory SummitÒ (Richmond & Charlotte) and the Southeastern Parkinson Disease Conference. She has written on the topic of caregiver self-care for the Every Victory CountsÒ program for the Davis Phinney Foundation. She is a co-leader with her husband Karl for the Fairfax City PD Support group in Fairfax, Virginia, US. She's a Virginia State Director for the Parkinson's Action Network and board member for the Parkinson Voice Project.
She is currently working with her husband Karl to promote his first book, A Soft Voice in a Noisy Word: A Guide to Dealing and Healing with Parkinson's Disease. She has a B.A. in Political Science/Public Policy from West Virginia University.
Angela Roberts-South (CANADA) completed her master’s degree in speech-language pathology in 1995 at the University of Tennessee. She pursued a clinical career in adult communication disorders prior to beginning her doctoral studies (2009) in the Health and Rehabilitation Sciences Program at Western University. She continues in a clinical capacity with the National Parkinson Foundation Centre of Excellence in London, Ontario. Her externally funded research interests include cognition and communication changes in Frontotemporal dementia and Parkinson disease.
Harold Robertson (CANADA)
Israel Robledo (USA) was diagnosed with Parkinson's disease in 2007at age 42.He became involved in advocacy work as a Parkinson's Disease Foundation Research Advocate through their signature Parkinson's Advocate in Research (PAIR) program. His areas of interest include educating the minority community about being actively involved in their health care and advocating for reimbursement of clinical trial-related expenses for participants. Israel is an elementary school reading specialist in Midland, Texas. He is married to Christi and has three daughters Amber, Ashley, Alisha and one grandson, Landon.
(UK) is a member of the Institute of Ageing and Health, Newcastle University and holds a BRC-funded Chair in Human Movement Science. She leads a research programme in gait and mobility disorders in age and age associated conditions within the Clinical Ageing Research Unit. Her main research interests concern gait, impact of ageing and pathology, interactions of non-motor and motor symptoms and their consequences on independent mobility, and development of interventions to improve mobility. Her studies include the development and testing of interventions to improve gait in Parkinson’s disease, application of novel technologies for assessment and intervention, such as accelerometry, and development of sensitive measures for improved diagnosis. She has published seminal translational studies defining and optimising methods to improve gait in Parkinson’s using external rhythmical stimulation which has led to changes in clinical practice worldwide following adoption into clinical guidelines.
Joanabbey Sack (Canada) is a registered Dance Movement Therapist and Drama Therapist with extensive additional training in the Social Sciences, Dance, Laban Movement Analysis, Theatre Arts and Music. Joanabbey was Dance Movement Therapist at the Montreal Children's Hospital for 12 years working in both Psychiatry and Medicine. She has been teaching at Concordia University in the Art Therapy Program and Creative Arts Therapies Graduate Program for twenty five years. She has been the Dance Movement Therapist and consultant at Concordia's Centre for the Arts in Human Development since 1996 and is currently Dance Movement Therapist and coordinator of the Speech Initiative at the Centre. In 2007 Joanabbey founded a project teaching dance to people with Parkinson’s -Parkinson’s Dance Project- in Montreal. This project has grown to include a series of classes, to include the Parkinsonenmouvement project and to develop research into participant response to the experience of Dance and LSVT BIG. Joanabbey has a private practice at the Queen Elizabeth Health Complex in Montreal.
Joanabbey Sack possède une maîtrise des Arts en thérapie par la danse et le mouvement de New York University et est membre reconnue (BC-DMT) par l'Association américaine de danse-thérapie (ADTA). Entre 1980 et 1992 elle a travaillé comme danse-thérapeute à l'Hôpital de Montréal pour enfants. Elle est conseillère en gestion du stress et entraîneuse privée. Depuis 1985 elle enseigne au programme de thérapie par les arts créatifs à l'Université de Concordia et depuis 1998 elle travaille comme danse-thérapeute au Centre des arts et du développement. Elle est chercheur pour le Centre des arts et du développement de l'Université Concordia. Joanabbey possède aussi une pratique privée à au Complexe de Santé Reine Elizabeth.
S. Pablo Sardi
(USA) is currently a research staff member at the Genetic Diseases Science Unit of Genzyme, a Sanofi Company. His present research interests are devoted to neurodegenerative and neurodevelopmental disorders. Pablo Sardi received a PharmD and MS degree in Biochemistry from the University of Buenos Aires, Argentina. He then obtained a PhD in Pharmacology from the School of Medicine, University of Buenos Aires. Pablo Sardi continued his post-doctoral education in the Neurobiology Department at Children’s Hospital Boston/Harvard Medical School. During this tenure, he discovered a presenilin-dependent pathway for tyrosine kinase receptors of critical relevance in neuronal gene regulation and differentiation. In 2007, Dr. Sardi moved to Genzyme Neuroscience where he currently leads a team studying the roles of Gaucher-mutations in Parkinson’s pathology. His team described the first animal model of Gaucher-related synucleinopathy and demonstrated that glucocerebrosidase augmentation in the brain constitutes a putative therapeutic approach for synucleinopathies including Parkinson’s disease.
Michael Schlossmacher (CANADA) is a clinician scientist focused on improving the lives of individuals with neurodegenerative diseases. Following completion of medical school in Vienna, Austria, he began graduate studies in human biology. In 1988, a Fulbright Commission scholarship enabled him to visit Harvard University. He subsequently pursed post-doctoral work on the molecular pathology of Alzheimer disease in the laboratory of Dr. Dennis J. Selkoe (1988-1992). This led to his discovery of the physiological release of amyloid beta-protein by cultured cells into biological fluids, which became an essential building block for the ‘amyloid hypothesis’ in Alzheimer disease.
Luca Scorrano (SWITZERLAND) received his MD in 1996 and his Ph.D. in 2000 from the University of Padova (Italy). After a postdoctoral fellowship in the lab of the late Stan Korsmeyer, he became an Assistant Scientist of the Dulbecco-Telethon Institute in 2003. From 2007 to 2013 he was Professor at the Dept. of Cell Physiology and Metabolism, University of Geneva (Switzerland). In 2013 he became Professor and Chair of Biochemistry at the Dept. of Biology, U. of Padova (Italy) His work contributed to change classical tenets in the field of apoptosis and mitochondrial pathophysiology. By combining genetics, advanced imaging, cell physiology and electron tomography his lab dissects the role of mitochondrial shape in cell life, differentiation, adaptation and death and explores the molecular nature of the tethers between mitochondria and the endoplasmic reticulum. For his work, he has received several national and international Awards and was elected Member of the EMBO in 2012.
Klaus Seppi (AUSTRIA) is a Professor for Neurology at the Department of Neurology at the Medical University Innsbruck. Dr. Klaus Seppi received medical training at the Medical University Innsbruck and completed the movement disorders fellowship at the Department of Neurology (Medical University Innsbruck). His research interests have been focused on the epidemiology of Movement Disorders, Neuroimaging of Parkinsonian disorders and evidence-based medicine in Movement Disorders.
Kapil Sethi (USA) who is Board-certified in Neurology and Internal medicine, earned his medical degree at the Christian Medical College, Ludhiana, India. After completing a research fellowship in neurology at the Charing Cross Group of Hospitals and Medical School, London, UK, he was a Registrar in Neurology at the Welsh National School of Medicine at Morriston Hospital, and a Neurology resident at the Medical College of Georgia.
Dr.Sethi is a Fellow of the American Academy of Neurology (AAN) and the Royal College of Physicians (London); the Vice President of the Tremor Research Group, and a member of the American Neurological Association (ANA), the Movement Disorder Society (MDS), and the American Association of Physicians from India. Dr.Sethi’s research interests are in Parkinson’s disease, restless legs syndrome, and cervical dystonia, and he has participated as principal investigator in numerous clinical trial and research studies.
An author of numerous reviews, abstracts, book chapters, and journal articles, Dr.Sethi’s work has been published in peer-reviewed publications, including Neurology, Movement Disorders and Annals of Neurology. He serves as an editorial reviewer for the journals Movement Disorders, Neurology, Brain, Annals of Neurology and The New England Journal of Medicine, and is a section editor for Current Neurology and Neurosciences Reviews and Medscape Neurology. He has served on the editorial boards of Movement Disorders and AAN.com.
Todd Sherer (USA) is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson's Research (MJFF), reporting to the Board of Directors. Formally trained as a neuroscientist, he directs the organization's research strategy and is responsible for the organization's overall scientific and fundraising direction to speed treatment breakthroughs and a cure for Parkinson's disease. Dr. Sherer has been a key architect of the Foundation's strategy to define high-priority research areas for Parkinson's disease - therapeutic targets and approaches that are closest or most critical to practical relevance in patients' daily lives - in order to leverage donor-raised capital to push projects in these areas toward the clinic. He has played a major role in the Foundation's efforts to increase the pharmaceutical industry's investment in Parkinson's disease drug development and engage the patient community to encourage and expand participation in clinical research. Today he is one of the world's foremost experts on the science and business of Parkinson's drug development, speaking frequently on these topics at conferences, to the media and to members of the Parkinson's community. Dr. Sherer's work with the Foundation began in 2003, when, as a postdoctoral fellow at Emory University in Atlanta, he was awarded MJFF funding to investigate the role of environmental factors in Parkinson's disease. He joined the Foundation's staff full time as Associate Director, Research Programs, in April 2004. He was promoted to Vice President, Research Programs, in June 2006 and Chief Program Officer in November 2010, finally assuming the role of Chief Executive Officer in May 2011. Dr. Sherer is a member of the Board of Directors of the Parkinson's Action Network and participates in the Institute of Medicine of the National Academies Forum on Neuroscience and Nervous System Disorders. He is a collaborating scientist for the Coalition Against Major Diseases (CAMD) and a member of the CINAPS Advisory Committee at the National Institute for Neurodegenerative Disease and Stroke, National Institutes of Health. During his career as a bench researcher, Dr. Sherer published over 30 peer-reviewed articles in scientific journals. He earned his PhD in Neuroscience from the University of Virginia and holds a BS in Psychology from Duke University in Durham, North Carolina.
David Simmonds (CANADA) was the first Chair of the newly federated Parkinson Society Canada. He has also served as Chair of the Community Foundation of Ottawa. Diagnosed with Parkinson's in 1993, he retired from practising law in 2000, and underwent deep brain stimulation surgery in 2011. Retirement has unleashed his passion for music and writing. He has recorded two albums 'The Parlour Recordings' and 'Dave's Car Wash', and writes a weekly column for his local newspaper, the Wellington Times. He has published a book of his columns, entitled 'Living off the Chipmunk Strut'. He lives in scenic Prince Edward County, Ontario, where he and his wife Dr. Michelle Simmonds frequently perform as part of the group 'Station Road'.
Jon Stamford (UK) is a neuroscientist with a double interest in Parkinson's. As well as leading a research laboratory investigating the neurochemistry of Parkinson's for more than a decade, Dr. Stamford also has young onset Parkinson's disease. He has published three neuroscience books and more than 200 research publications (reviews, papers, abstracts) in an academic career lasting 23 years.He holds an honorary readership at the University of Leicester, andis a scientific consultantand member of the patient advocates groupwith the Cure Parkinson's Trust.Jon also writes a humorous and influentialweekly blog "Slice of Life"about life with young onset Parkinson's
David Standaert (USA) graduated from Harvard College in 1982. He received his M.D. and Ph.D. degrees from Washington University in St. Louis. He completed a one-year internship in Medicine followed by a three-year Neurology residency at the University of Pennsylvania. He was appointed a Howard Hughes Medical Institute Physician Research Fellow, and completed a three-year research and clinical fellowship in Neurology (Movement Disorders) at Massachusetts General Hospital in 1995. He subsequently joined the faculty at Harvard Medical School and MGH, where he served as Director of the MGH/MIT Udall Center of Excellence in PD Research. Dr. Standaert relocated to the University of Alabama at Birmingham in July of 2006 and is now the John N. Whitaker Professor and Chair of the Department of Neurology. He serves as Director of the Division of Movement Disorders, the Director of the APDA Advanced Center for Parkinson Research at UAB, and is the Director of the Center for Neurodegeneration and Experimental Therapeutics. He sees patients in a weekly clinic and oversees many clinical trials for new treatments of Parkinson's disease. He is a member of the Scientific Advisory Boards of the Michael J. Fox Foundation for Parkinson Research, the American Parkinson Disease Association, and the Bachmann-Strauss Dystonia & Parkinson Foundation. Dr. Standaert’s laboratory works on understanding both the root causes of Parkinson’s disease as well as the origin of the disabling symptoms that appear after long term treatment of the disease. Recently, his group has focused on approaches to reducing the toxicity of synuclein in animal models of Parkinson disease, and the role of neuroinflammatory reactions in disease progression.
Leonidas Stephanis (GREECE) obtained his MD and PhD from the University of Athens Medical School in 1987 and 1992 respectively. In 1991, he moved to the US, where he trained as Resident in Neurology at Columbia University in New York. In 1995, he embarked on a post-doctoral fellowship on mechanisms of neuronal cell death in the laboratory of Dr. Lloyd Greene, in the Dept. of Pathology, while in parallel he completed a two-year fellowship on Neurobehaviour, in the Dept. of Neurology at Columbia University. In 1998 he was appointed Assistant Professor of Neurology in the Dept. of Neurology at Columbia University, position which he held up till 2003. During this time, he focused his interest on the pathogenesis of neurodegenerative disorders. In 2003 he moved back to Greece as Researcher Level B at the Biomedical Research Foundation of the Academy of Athens (BRFAA), and set up a laboratory focusing on mechanisms of neurodegeneration, in particular in relation to protein degradation systems, alpha-synuclein and PD. Since 2006 he has assumed the appointment of Associate Professor of Neurology and Neurobiology in the University of Athens Medical School, while he continues his work at BRFAA as an affiliated investigator. Currently, Dr. Stefanis is investigating various areas of PD pathogenesis, ranging from the bench to the bedside. He is examining the genetic underpinnings of the disease in the Greek population in rare familial, but also in sporadic cases. He is involved in studies that examine the utility of using alpha-synuclein as a disease biomarker. He is examining pathways of neurotoxicity induced by aberrant alpha-synuclein, with an emphasis on the involvement of protein degradation pathways, such as Chaperone-Mediated Autophagy. He is also investigating the molecular underpinnings of other genetic alterations linked to PD, such as those in UCH-L1, LRRK2 and GBA.
Gerald Stern (UK) Emeritus consultant neurologist, University College Hospitals Queen Square London UK. Formerly Surgeon Lieutenant Royal Navy Volunteer Reserve. He trained at University College London, Columbia University New York USA. University of Durham UK and La Salpetriere University of Paris France. Past-President of the Association of British ,Neurologists, past Vice-President of the Royal Society of Medicine. Corresponding Member of the American Neurological Association, Ehrenmitgleid Ostereischiche Parkinsn Geselschaft, Recipient of Burda Prize for research into Parkinson’s disease, Royal Society of Medicine visiting professor to the United States and American College of Neuropsychopharmacology, Thomas Greenaway visiting Lecturer of Royal Australasian College of Physicians, Alice Wilson visiting Professor University of Kansas and visiting professor at other universities in USA, Europe and South-East Asia. Honorary Member and Stanley Fahn Lecturer of the Movement Disorder Society. His clinical work and research interests have been mainly in the field of movement disorders and Parkinson’s disease, the neurodegenerations and general neurology. He has published over 350 peer-reviewed articles and several books. He had a longstanding interest in James Parkinson – both were brought up in the same part of London and both studied at the London hospital - but not at the same time.
Fabrizio Stocchi (ITALY) is Professor of Neurology, Consultant in Neurology and Director of the Parkinson’s disease and Movement disorders research centre at the Institute for Research and Medical Care IRCCS San Raffaele Rome and University "La Sapienza” Rome. He is also Scientific advisor of the Institute for Parkinson’s Disease Research in Vicenza. Professor Stocchi was awarded his MD from the University of L’Aquila and his PhD from the University of Catania. Professor Stocchi’s research activities have centred on neuropharmacology in the field of movement disorders and neurodegenerative diseases. He has published many books and papers on the genetics, clinical diagnosis, characterisation and treatment of Parkinson’s disease, as well as in preclinical research into the disease. He is an active member of 11 societies, including the Movement Disorders Society, the WFN society where is member of the extrapiramidal committee, the European Clinical Neuropharmacology Society and the European Federation Neurological Society.
A. Jon Stoessl (CANADA), Professor and Head of Neurology and Director of the Pacific Parkinson's Research Centre and National Parkinson Foundation Centre of Excellence at UBC and Vancouver Coastal Health and been tapped to co-chair the third World Parkinson Congress. He holds a Tier 1 Canada Research Chair in Parkinson's Disease and directs the CIHR Team in Parkinson's and a Pacific Alzheimer Research Foundation Centre grant on Overlap Syndromes Resulting in Dementia.
When asked about his appointment as co-chair, he said, "I am delighted to co-chair the third World Parkinson Congress and look forward to an outstanding program and experience for the delegates who join us in Montreal, Canada in October 2013. I expect the WPC 2013 to follow the success of the first two Congresses with a high caliber scientific program designed to bring the community together and to build excitement around the latest research from both basic and clinical scientists as well as rehab specialists. I also see this as the perfect space to highlight ongoing programs that are helping people with Parkinson's take charge of their lives and live more independently. Working together as a community, we can make advances more quickly. I expect the WPC 2013 to draw record numbers because of the excitement generated in Glasgow and because of the beauty and charm of Montreal. I look forward to welcoming delegates to Canada."
Dr. Stoessl has worked closely with the Parkinson Society Canada as their past Chair of the Scientific Advisory Board for and is well respected among his peers and the community of people living with Parkinson's across Canada. When she learned of Dr. Stoessl's co-chair position, Joyce Grodon, President and CEO of Parkison Society Canada said, "Dr. Stoessl is a recognized leader in the Canadian and International Parkinson community and Parkinson Society Canada is delighted to have him at the helm with Dr. Fahn for WPC 2013."
Dr. Stoessl sits on the editorial boards of numerous journal and has served on a number of scientific advisory boards, including Canadian Institutes of Health Research, Ontario Mental Health Foundation (Chair), Huntington Society of Canada, Tourette Syndrome Association and National Parkinson Foundation. and currently chairs the Interdisciplinary Adjudication Committee of the Canada Research Chairs program. In 2007, he was appointed a Member of the Order of Canada . Dr. Stoessl's research involves the use of positron emission tomography to study Parkinson's disease and related disorders, including the use of imaging as a biomarker, the basis for complications of treatment and mechanisms of the placebo effect. He has published more than 220 papers and book chapters.
Antonio Strafella (CANADA) is a Canada Research Chair in Movement disorders and Neuroimaging, an Associate Professor in the Dept. of Medicine/Neurology at UHN, University of Toronto, Senior Scientist in the Division of Brain Imaging & Behaviour Systems at the Toronto Western Research Institute and Senior Scientist in the Research Imaging Centre at CAMH. He is using a number of PET tracers and novel radio-ligands to investigate the pathophysiology of motor, cognitive (e.g. MCI) and behavioral symptoms (e.g. ICDs) in Parkinson’s disease.
Oksana Suchowersky (CANADA) is a Professor of Medicine, Medical Genetics, and Psychiatry, and the Toupin Research Chair in Neurology at the University of Alberta. Prior to 2011, she was Professor in the Departments of Clinical Neurosciences and Medical Genetics, Faculty of Medicine, University of Calgary, Co- Director of the Movement Disorders Program at the Hotchkiss Brain Institute, and Head of the Department of Medical Genetics (2005-2010). Her research interests lie in the management of movement disorders, diagnosis of neurological genetic disorders, and genetics testing of adult-onset hereditary disorders. She serves on several editorial boards including Nature Clinical Practice Neurology. She has over over 200 peer-reviewed publications and is the editor of 2 books on Movement Disorders. Dr. Suchowersky has received a number of awards over the years, and has been named as one of the Best Doctors of Canada.
Carolyn Sue (AUSTRALIA) is currently appointed as Professor and Head of the Department of Neurology at Royal North Shore Hospital, University of Sydney. She trained in the study of movement disorders with Professor John Morris and continued her post-doctoral studies at Columbia University, New York, USA. Dr Sue’s research interests are focused on two main areas: the role of mitochondrial function in neurodegenerative disease and the genetics of movement disorders. Dr Sue founded the Familial Parkinson’s Disease Research Clinic at Royal North Shore Hospital, and has coordinated national collaborative genetic studies in Parkinson’s disease. Most recently, her research group has established the use of patient derived stem cell models to investigate the pathophysiology underlying Parkinson’s disease.
James Surmeier (USA) is the Nathan Smith Davis Professor and Chair of the Department of Physiology at the Feinberg School of Medicine at Northwestern University and Director of the Morris K. Udall Research Center of Research Excellence for Parkinson’s Disease at Northwestern University. Dr. Surmeier received his Ph.D. in Physiology and Biophysics from the University of Washington in 1983. He trained with leaders in the field of neurophysiology, including Dr. Arnold Towe, Dr. William Willis, and Dr. Stephen Kitai. In 1998, he moved to the Department of Physiology at Northwestern University and assumed his current position in 2001. Dr. Surmeier’s research program focuses on the basal ganglia – neural structures controlling movement and intimately involved in the pathophysiology of Parkinson’s and Huntington’s diseases. He has authored over 150 peer-reviewed publications in journals such as Science, Nature, Neuron, Nature Neuroscience and the Journal of Neuroscience. He has served in several advisory capacities to the National Institutes of Health, including chairing study sections for the National Institute of Neurological Disorders and Stroke (NINDS) and acting as a Councilor for NIAAA. He also serves on the scientific advisory boards of several private foundations and serves on a number of editorial boards, including Molecular and Cellular Neuroscience, Neuron and Current Opinion in Neurobiology. He was elected as a Fellow of the American Association for the Advancement of Science and has received many other scientific awards including the NARSAD Established Investigator award and the Jacob Javits Neuroscience Investigator Award.
Louis Tan (SINGAPORE) is a Senior Consultant Neurologist with the National Neuroscience Institute, Singapore (TTSH campus) and also the Co-Director of the Parkinson’s Disease and Movement Disorders Centre there. In 2006, the Centre received the distinction of being an International Centre of Excellence for the United States based National Parkinson Foundation (NPF) for Parkinson-related research, comprehensive care and community outreach. He is an Adjunct Associate Professor of Duke-NUS Graduate Medical School, Singapore. He is the Chair of the Asian and Oceanian Section of the Movement Disorder Society and the past-Chair of the MDS Education Committee. Upon graduating from the National University of Singapore and completing his neurology training at Tan Tock Seng Hospital, he underwent a movement disorders fellowship at the Parkinson’s Institute in Sunnyvale, California. His areas of specialty and research interests are Parkinson’s disease and movement disorders. He is also interested in the interested in the epidemiology, clinical studies and clinical trials in Parkinson’s disease and other movement disorders.
(CANADA) is a former physiotherapist who has worked in Canada, Australia, New Zealand and the UK. Her main area of expertise and interest was neurological rehabilitation. In 2000, just as she was transitioning to a new career in Teaching English as a Second Language, she was diagnosed with Parkinson’s Disease. Currently, she volunteers in an adult ESL program and supply teaches on an occasional basis to maintain her certification. Alice is an active volunteer with Parkinson Society Ottawa (PSO). She was a member of the PSO Program Committee and currently serves on the Outreach and Engagement Committee. She helps manage the PSO Resource Library, has participated in the planning of PSO's annual Perspectives on Parkinson's Symposium for several years and assists with other special events as needed. She received PSO’s Volunteer of the Year Award for 2010. As well, she serves on the WPC 2013 Program Planning Subcommittee for Interdisciplinary Care and on the Parkinson’s Advocates Committee. In 2010, she completed the 800-km Camino de Santiago, a personal highlight, while also raising funds for PSO. She is proactive in managing her Parkinson’s and advocates keeping as active and engaged as possible.
(USA) is an Assistant Clinical Professor of Neurology, and Program Director of the Parkinson's Disease and Movement Disorder Center at Boston University Medical Campus (BUMC). She is the nurse coordinator of the APDA Information and Referral and Advanced Center of Research at BUMC. Ms. Thomas has worked extensively with individuals with Parkinson's disease and their families for greater than twenty-five years. As a Clinical Nurse Specialist in neurorehabilitation, she has developed novel programs to assess the impact of Parkinson's disease on a patient and family and provide education to assist in coping with this condition. Her research activities have included participation in over forty clinical studies. She is an active member of the Parkinson Study Group and currently serves on the scientific review committee. She has co-authored Parkinson's Disease, A Guide to Patient Care.
Ryan Tripp (CANADA) was diagnosed with Parkinson ‘s disease in July of 1996, at an age of 47 years old. He worked as a P.E. teacher and administrator for 23 years. Two and a half year’s later he was forced to take a long-term disability health leave from his profession. This lead to a major slip into depression, a fractured marriage and a stage of 'who am I and what is happening to me?!?' After joining a PD support group, improved medication and some valuable counseling, he found a renewed focus on life and living with Parkinson’s. His active involvement in events and speaking engagements outside of P.S.C. has brought him a wealth of information, contacts and experiences that are extensive and invaluable. Finally, inside P.S.C., he has been a strong consistent fundraiser, an active committee volunteer, an enthusiastic advocate in the community, on Parliament Hill and at Queen’s Park in Canada, plus he started and led a local support group in Muskoka, Ontario. His personal code is to live with intention, walk to the edge, listen hard, practice wellness, play with abandon, laugh, choose, with no regret, continue to learn, appreciate your friends, do what you love, and, live as if this is all there is!
Alexander Troster (USA) a clinical neuropsychologist, is a Professor and Senior Scientist at Barrow Neurological Institute. He obtained his doctorate in clinical neuropsychology at the University of California San Diego and San Diego State University. The author of more than 160 scientific and medical journal articles and numerous book chapters, Dr. Tröster is primarily interested in cognition in movement disorders, the role of basal ganglia in cognition, and neuropsychological outcomes of stereotactic and functional neurosurgery, especially deep brain stimulation. His contributions were recognized with fellowships in the National Academy of Neuropsychology and the American Psychological Association. He is immediate past president of the National Academy of Neuropsychology, a society from which he received both the distinguished scientific contributions to clinical neuropsychology and the early career achievement awards. He serves on the editorial boards of five scientific journals and several advisory boards and is an examiner for the American Board of Clinical Neuropsychology.
Leonard Verhagen (USA) is a Professor of Neurological Sciences in the Movement Disorders Group at Rush University Medical Center in Chicago, IL. In addition he is Medical Director of the Movement Disorder Surgery Program at Rush. He specializes in the medical and surgical management of patients with Parkinson's disease and other Movement Disorders such as Essential Tremor and Dystonia.Dr. Verhagen earned his medical degree from the University of Leiden in the Netherlands in 1983. After coming to the United States in 1985 to work in the Division of Artificial Organs at the University of Utah, he decided to pursue his interest in the Neurosciences and accepted a research fellowship in the Division of Restorative Neurology and Human Neurobiology at Baylor College of Medicine in Texas. Subsequently, he started his Neurology residency at Thomas Jefferson University Hospital in Philadelphia. Upon completion in 1992, he accepted a fellowship at the National Institutes of Health, in the Experimental Therapeutics Branch of the National Institute of Neurological Disorders and Stroke. After completion of this fellowship in 1994, he stayed at the NIH for another 5 years, first as visiting Associate, later as visiting Scientist. The Branch’s main focus was on pharmacological studies of motor response complications in Parkinson's disease. In 1999 he joined the Movement Disorder Section of the Department of Neurological Sciences at Rush University Medical Center, one of the largest movement disorder centers in the USA. In 2002 Dr. Verhagen earned his doctorate degree for the University of Leiden based on his studies of motor response complications in Parkinson's disease. Over the past 14 years at Rush, Dr. Verhagen has been Medical Director of the Rush Movement Disorder Surgery program. He continues to work with his colleagues on better medical and surgical treatments for patients with movement disorders through clinical research
Miquel Vila (SPAIN) received his M.D. from the University of Barcelona Medical School (Barcelona, Spain) in 1993. He then moved to the laboratory of Experimental Neurology and Therapeutics, INSERM U289 (Prof. Yves Agid) at the Salpêtrière Hospital in Paris (France), where he obtained his Master degree (D.E.A.) and Ph.D. in Neuroscience from the University of Paris VI (Pierre et Marie Curie), under the supervision of Dr. Etienne Hirsch. His Ph.D. work was devoted to the study of the functional consequences of dopaminergic neurodegeneration on the functioning of the basal ganglia. From 1998 to 2001, he worked as a postdoctoral researcher at the laboratory of Dr. Serge Przedborski at the Department of Neurology, Movement Disorders Division, at Columbia University (New York, USA), focusing on the molecular mechanisms of neuronal death in Parkinson's disease. To continue his work, he obtained in 2001 a position as an Assistant Professor of Neurology at Columbia University. In December 2005, he moved back to Barcelona as a Research Professor at ICREA (Catalan Institution for Research and Advanced Studies) to develop a new research lab on Neurodegeneration at the Vall d’Hebron Research Institute (VHIR), thanks to the support of the European Commission’s Marie Curie Excellence Grants program. In addition, he holds positions as Associate Professor at the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona (UAB) and as Principal Investigator of the Spanish Network of Excellence on Neurodegenerative Diseases (CIBERNED).
Cheryl Waters (USA) is the Albert B. and Judith L. Glickman Professor of Neurology in the Division of Movement Disorders at Columbia University, New York, New York. Dr. Waters received her BSc and MSc in pharmacology and MD from the University of Toronto in Ontario, Canada, where she studied dopamine receptor function with Professor Philip Seeman. Following an internship at the University of Chicago Pritzker School of Medicine, she returned to the University of Toronto to complete her residencies in internal medicine and neurology and pursue a research fellowship in neurology and clinical pharmacology. She founded and headed the Division of Movement Disorders and served on the faculty in the Department of Neurology at the University of Southern California in Los Angeles prior to taking her current position at Columbia University. Dr. Waters is the Principal Investigator of over 60 clinical trials on Parkinson’s disease and an active member of the Parkinson Study Group, a Fellow of the American Academy of Neurology (FAAN), and American Neurological Association (FANA) and the Royal College of Physicians in Canada. She has taught several AAN courses. Dr. Waters has published more than 200 journal articles, abstracts, reviews, book chapters, case reports, and a book entitled, Diagnosis and Management of Parkinson’s disease now in its sixth edition.
Daniel Weintraub (USA) is Associate Professor of Psychiatry and Neurology at the University of Pennsylvania and Psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center. A board-certified geriatric psychiatrist, he conducts clinical research in the psychiatric and cognitive complications of Parkinson’s disease and Alzheimer's disease, and is author of more than 100 journal articles, reviews, and book chapters. He completed a NIMH Career Development Award titled "Depression Diagnosis and Treatment in Parkinson Disease”, and has also been Principal Investigator on grants from the VA, the Institute of Aging at Penn, the Fox Foundation for Parkinson’s Research, and several industry-sponsored studies. His research has focused on the epidemiology, neural substrate, assessment and treatment of depression, psychosis, cognitive impairment and impulse control disorders in Parkinson’s disease. Dr. Weintraub previously served as an Advisor to the Cognitive Work Group of the DSM-V Task Force, was Chair of the Psychiatry Subgroup of the NINDS Common Data Elements (CDE) project, and has been a member of five Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of cognitive and psychiatric symptoms in Parkinson’s disease. He currently is on the Editorial Board of Movement Disorders and the Journal of Parkinson’s Disease, a member of the Scientific Advisory Committee of the Lewy Body Dementia Association, on the DSMB’s for Alzheimer's Disease Cooperative Study (ADCS) and ENROLL-HD study sponsored by the Cure Huntington’s Disease Initiative, on the Executive Committee of the Parkinson Study Group (PSG), serves on the Movement Disorder Society Scales Development Committee and the Non-Motor Symptoms Workgroup, and was recently appointed Chair of the Cognitive-Behavioral Work Group for the Parkinson’s Progression Markers Initiative (PPMI) study.